<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical ophthalmic anesthetics for corneal abrasions - Sulewski, M - 2023 | Cochrane Library</title> <meta content="Topical ophthalmic anesthetics for corneal abrasions - Sulewski, M - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015091.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical ophthalmic anesthetics for corneal abrasions - Sulewski, M - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015091.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015091.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical ophthalmic anesthetics for corneal abrasions" name="citation_title"/> <meta content="Michael Sulewski" name="citation_author"/> <meta content="The Johns Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="Louis Leslie" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Su-Hsun Liu" name="citation_author"/> <meta content="Cristos Ifantides" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Kyongjin Cho" name="citation_author"/> <meta content="Dankook University, College of Medicine" name="citation_author_institution"/> <meta content="Irene C Kuo" name="citation_author"/> <meta content="The Johns Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="ickuo@jhmi.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD015091.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/08/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015091.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015091.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015091.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics; *Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; *Corneal Injuries [drug therapy]; Pain, Postoperative" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015091.pub2&amp;doi=10.1002/14651858.CD015091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015091\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015091\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015091.pub2",title:"Topical ophthalmic anesthetics for corneal abrasions",firstPublishedDate:"Aug 9, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015091.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015091.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015091.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015091.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015091.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015091.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015091.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015091.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015091.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015091.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1626 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015091.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/appendices#CD015091-sec-0102"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/supinfo/CD015091-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/supinfo/CD015091-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical ophthalmic anesthetics for corneal abrasions</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#CD015091-cr-0004">Michael Sulewski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#CD015091-cr-0005">Louis Leslie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#CD015091-cr-0006">Su-Hsun Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#CD015091-cr-0007">Cristos Ifantides</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#CD015091-cr-0008">Kyongjin Cho</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information#CD015091-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Irene C Kuo</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information/en#CD015091-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 August 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015091.pub2">https://doi.org/10.1002/14651858.CD015091.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015091-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015091-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015091-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015091-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015091-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015091-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015091-abs-0001" lang="en"> <section id="CD015091-sec-0001"> <h3 class="title" id="CD015091-sec-0001">Background</h3> <p>Despite potential analgesic benefits from topical ophthalmic amides and esters, their outpatient use has become of concern because of the potential for abuse and ophthalmic complications. </p> </section> <section id="CD015091-sec-0002"> <h3 class="title" id="CD015091-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of topical ophthalmic anesthetics compared with placebo or other treatments in persons with corneal abrasions. </p> </section> <section id="CD015091-sec-0003"> <h3 class="title" id="CD015091-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; Embase.com; Latin American and Caribbean Health Sciences (LILACS); ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), without restriction on language or year of publication. The search was performed on 10 February 2023. </p> </section> <section id="CD015091-sec-0004"> <h3 class="title" id="CD015091-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) of topical ophthalmic anesthetics alone or in combination with another treatment (e.g. nonsteroidal anti‐inflammatory drugs (NSAIDs)) versus a non‐anesthetic control group (e.g. placebo, non‐treatment, or alternative treatment). We included trials that enrolled participants of all ages who had corneal abrasions within 48 hours of presentation. </p> </section> <section id="CD015091-sec-0005"> <h3 class="title" id="CD015091-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology.</p> </section> <section id="CD015091-sec-0006"> <h3 class="title" id="CD015091-sec-0006">Main results</h3> <p>We included nine parallel‐group RCTs with a total of 556 participants (median number of participants per study: 45, interquartile range (IQR) 44 to 74), conducted in eight countries: Australia, Canada, France, South Korea, Turkey, New Zealand, UK, and USA. </p> <p><b>Study characteristics and risk of bias</b> </p> <p>Four RCTs (314 participants) investigated post‐traumatic corneal abrasions diagnosed in the emergency department setting. Five trials described 242 participants from ophthalmology surgery centers with post‐surgical corneal defects: four from photorefractive keratectomy (PRK) and one from pterygium surgery. Study duration ranged from two days to six months, the most common being one week (four RCTs). Treatment duration ranged from three hours to one week (nine RCTs); the majority were between 24 and 48 hours (five RCTs). The age of participants was reported in eight studies, ranging from 17 to 74 years of age. Only one participant in one trial was under 18 years of age. Of four studies that reported funding sources, none was industry‐sponsored. We judged a high risk of bias in one trial with respect to the outcome pain control by 48 hours, and in five of seven trials with respect to the outcome complications at the furthest time point. The domain for which we assessed studies to be at the highest risk of bias was missing or selective reporting of outcome data. </p> <p><b>Findings</b> </p> <p>The treatments investigated included topical anesthetics compared with placebo, topical anesthetic compared with NSAID (post‐surgical cases), and topical anesthetics plus NSAID compared with placebo (post‐surgical cases). </p> <p><b>Pain control by 24 hours</b> </p> <p>In all studies, self‐reported pain outcomes were on a 10‐point scale, where lower numbers represent less pain. In post‐surgical trials, topical anesthetics provided a moderate reduction in self‐reported pain at 24 hours compared with placebo of 1.28 points on a 10‐point scale (mean difference (MD) −1.28, 95% confidence interval (CI) −1.76 to −0.80; 3 RCTs, 119 participants). In the post‐trauma participants, there may be little or no difference in effect (MD −0.04, 95% CI −0.10 to 0.02; 1 RCT, 76 participants). Compared with NSAID in post‐surgical participants, topical anesthetics resulted in a slight increase in pain at 24 hours (MD 0.82, 95% CI 0.01 to 1.63; 1 RCT, 74 participants). </p> <p>One RCT compared topical anesthetics plus NSAID to placebo. There may be a large reduction in pain at 24 hours with topical anesthetics plus NSAID in post‐surgical participants, but the evidence to support this large effect is very uncertain (MD −5.72, 95% CI −7.35 to −4.09; 1 RCT, 30 participants; very low‐certainty evidence). </p> <p><b>Pain control by 48 hours</b> </p> <p>Compared with placebo, topical anesthetics reduced post‐trauma pain substantially by 48 hours (MD −5.68, 95% CI −6.38 to −4.98; 1 RCT, 111 participants) but had little to no effect on post‐surgical pain (MD 0.41, 95% CI −0.45 to 1.27; 1 RCT, 44 participants), although the evidence is very uncertain. </p> <p><b>Pain control by 72 hours</b> </p> <p>One post‐surgical RCT showed little or no effect of topical anesthetics compared with placebo by 72 hours (MD 0.49, 95% CI −0.06 to 1.04; 44 participants; very low‐certainty evidence). </p> <p><b>Proportion of participants with unresolved epithelial defects</b> </p> <p>When compared with placebo or NSAID, topical anesthetics increased the number of participants without complete resolution of defects in trials of post‐trauma participants (risk ratio (RR) 1.37, 95% CI 0.78 to 2.42; 3 RCTs, 221 participants; very low‐certainty evidence). The proportion of placebo‐treated post‐surgical participants with unresolved epithelial defects at 24 to 72 hours was lower when compared with those assigned to topical anesthetics (RR 0.14, 95% CI 0.01 to 2.55; 1 RCT, 30 participants; very low‐certainty evidence) or topical anesthetics plus NSAID (RR 0.33, 95% CI 0.04 to 2.85; 1 RCT, 30 participants; very low‐certainty evidence). </p> <p><b>Proportion of participants with complications at the longest follow‐up</b> </p> <p>When compared with placebo or NSAID, topical anesthetics resulted in a higher proportion of post‐trauma participants with complications at up to two weeks (RR 1.13, 95% CI 0.23 to 5.46; 3 RCTs, 242 participants) and post‐surgical participants with complications at up to one week (RR 7.00, 95% CI 0.38 to 128.02; 1 RCT, 44 participants). When topical anesthetic plus NSAID was compared with placebo, no complications were reported in either treatment arm up to one week post‐surgery (risk difference (RD) 0.00, 95% CI −0.12 to 0.12; 1 RCT, 30 participants). The evidence is very uncertain for safety outcomes. </p> <p><b>Quality of life</b> </p> <p>None of the included trials assessed quality of life outcomes.</p> </section> <section id="CD015091-sec-0007"> <h3 class="title" id="CD015091-sec-0007">Authors' conclusions</h3> <p>Despite topical anesthetics providing excellent pain control in the intraoperative setting, the currently available evidence provides little or no certainty about their efficacy for reducing ocular pain in the initial 24 to 72 hours after a corneal abrasion, whether from unintentional trauma or surgery. We have very low confidence in this evidence as a basis to recommend topical anesthetics as an efficacious treatment modality to relieve pain from corneal abrasions. We also found no evidence of a substantial effect on epithelial healing up to 72 hours or a reduction in ocular complications when we compared anesthetics alone or with NSAIDs versus placebo. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015091-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015091-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015091-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015091-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015091-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015091-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015091-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015091-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015091-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015091-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015091-abs-0002" lang="en"> <h3>What are the benefits and unwanted effects of topical anesthetics for corneal abrasions?</h3> <p><b>Key message(s)</b> </p> <p>1. We are very uncertain about the effectiveness of anesthetic eye drops for control of pain due to corneal abrasions (scratches). </p> <p>2. We are very uncertain about the safety of anesthetic eye drops regarding speed of healing and complications. </p> <p>3. To ensure trustworthy evidence, researchers should follow best‐practice guidance. Future research studies should include more people followed over a longer period of time after treatment ends. </p> <p><b>What is a corneal abrasion?</b> </p> <p>A corneal abrasion is a scratch on the clear outer layer of the eye. These scratches can be caused by fingernails, dust, dirt, wood, twigs, thorns, or metal shavings blown or pushed into the eye. Improper use of contact lenses sometimes results in minor but painful scratches on the cornea. Some eye surgeries, like one type of laser refractive surgery, may require deliberately creating an abrasion. The symptoms of corneal abrasion include eye pain, blurred vision, grittiness, excessive tearing, redness, light sensitivity, or even headache. </p> <p><b>How are corneal abrasions treated?</b> </p> <p>Non‐medicine‐based care of corneal abrasions includes eye rinse with clean water or normal saline and frequent blinking. Although most minor scratches on the cornea can heal on their own, they are typically treated with antibiotic eye drops or ointment to prevent infections. Sometimes, doctors prescribe topical painkillers to reduce eye pain, such as anesthetics (medications that lower the sense of pain) and nonsteroidal anti‐inflammatory drugs (NSAIDs). </p> <p><b>What did we want to find out?</b> </p> <p>We assessed whether anesthetic eye drops reduce pain in people with corneal abrasions. We also examined whether anesthetic eye drops influence the healing of the corneal wound or cause unwanted effects on the eyes. </p> <p><b>What did we do?</b> </p> <p>We performed a systematic review by searching for studies that compared anesthetic eye drops with no treatment, inactive eye drops, or a different medication. We summarized the review findings and reported results along with our confidence about the evidence based on the study design and method. </p> <p><b>What did we find?</b> </p> <p>We found nine studies that had enrolled 556 people aged 17 years or older. Four studies took place in hospital emergency care settings and five took place in eye surgery settings. Most studies were one week long, but their length ranged from two days (one study) to six months (another study). Only four studies reported funding sources, none of which were drug companies. </p> <p>In comparison with inactive treatment, anesthetic eye drops alone were effective in reducing eye pain up to 24 hours after treatment and may also be effective when combined with NSAIDs. When compared with NSAIDs, the anesthetic eye drops alone were slightly less effective at pain control. At 48 hours, anesthetics alone decreased eye pain relative to inactive eye drops but were no more effective at 72 hours. Anesthetic eye drops resulted in a slight delay in wound healing up to 72 hours after treatment. Other complications, such as infections, were slightly more frequent with anesthetics, but these complications were similar between groups up to one week after treatment. There were too few studies to know whether people responded to treatment differently when the abrasion was from an injury or from eye surgery. No study looked at quality of life. </p> <p>The evidence for all outcomes in this review is very uncertain. Further research studies that enroll larger numbers of participants and follow them for at least one week are likely to change our findings. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are not confident of the conclusions suggested by the evidence found for this review of the effectiveness and safety of anesthetic eye drops because of the flawed collection and reporting of data, and the small size of the studies. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The evidence is up‐to‐date as of 10 February 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015091-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015091-sec-0095"></div> <h3 class="title" id="CD015091-sec-0096">Implications for practice</h3> <section id="CD015091-sec-0096"> <p>Corneal abrasions from trauma or epithelial defects created during ophthalmic surgery present commonly in clinical practice. Safely managing pain is therefore of great interest. With a growing opioid crisis in the United States, opioid‐sparing pain management is a favorable option. Although topical anesthetics provide excellent pain control in the intraoperative setting, they traditionally have not been prescribed for outpatient use. </p> <p>Compared with placebo, topical anesthetics alone or combined with a nonsteroidal anti‐inflammatory drug (NSAID) have been shown to be effective in reducing pain up to 24 hours in post‐surgical patients. Compared with NSAIDs, topical anesthetics may be slightly less effective at pain control in post‐surgical patients. At 48 hours, topical anesthetics decreased pain relative to placebo but were no more effective at 72 hours. Very low‐certainty evidence regarding complications within seven days favored placebo in post‐surgical participants. </p> <p>Despite a lack of evidence of efficacy or safety differences between topical anesthetic and placebo in accidental or surgically created corneal abrasions, use of anesthetic eye drops without close monitoring creates a potential for ocular morbidity. We wish to highlight that the studies in this review were characterized by very close follow‐up of participants, use of an often diluted anesthetic mixture, and dispensing of a very limited supply. Despite the fact that we found no differences in safety (e.g. complications at longest follow‐up) the evidence was of very low certainty and, therefore, we do not discount the case literature describing a typified pattern of abuse. Similar to the use of topical steroids or NSAIDs, the risk of adverse effects increases when anesthetic drops are used more frequently or for longer than recommended. It is not difficult to imagine that a practice pattern shift towards liberalization of topical anesthetic prescribing could lead to situations far beyond the controlled environments of the studies we reviewed: where larger quantities are dispensed, follow‐up is not ensured, or where other providers reflexively renew prescription refills. Furthermore, case series in the ophthalmic literature indicate that patients who abuse topical anesthetics may have a psychiatric disorder, history of drug abuse, or history of depression. It is possible that such patients demand anesthetic agents because of heightened pain awareness. However, it is not clear whether emergency rooms have the resources to screen patients for these disorders prior to prescribing topical anesthetics and to counsel them on the importance of follow‐up with an ophthalmologist. All trials included in this review were characterized by very short follow‐up, which may not have allowed such complications to manifest. Patients recruited in the emergency department setting had higher dropout rates than post‐surgery patients, which raises the potential for misuse compared with surgical patients who have close follow‐up by an ophthalmic surgeon for a defect created in a sterile field. The latter may be reasons for newer modalities to be used to treat post‐photorefractive keratectomy pain that may be inappropriate for use to relieve pain from abrasions that present in non‐surgical settings. </p> </section> <h3 class="title" id="CD015091-sec-0097">Implications for research</h3> <section id="CD015091-sec-0097"> <p> <ul id="CD015091-list-0011"> <li> <p>Investigators planning future trials on the safety and efficacy of topical anesthetics should plan for a larger sample size of diverse participant populations and both shorter (e.g. first eight hours) and longer (e.g. over one week) follow‐up periods to assess critical outcomes and rare or non‐immediate complications. Sample size assumptions (effect size, power) should be justified. Traumatic corneal abrasions account for more than 10% of eye‐related emergency room visits, which would indicate the potential for RCTs with larger enrollment than the RCTs in this review. Attrition should be reported and investigated, with attempts made to contact such patients for possible risk of anesthetic abuse. One concern with topical anesthetics prescribed on an outpatient basis for corneal abrasions is that patients who obtain prescriptions from multiple emergency rooms and do not follow up with either an emergency room physician or an ophthalmologist are at risk for anesthetic abuse‐related corneal complications. The situation would be analogous to the opioid crisis where providers were not versed in prescribing opioids (or in some cases were incentivized) and patients became addicted. </p> </li> <li> <p>Efficacy outcomes should include a more complete understanding of pain; participant‐reported functional and quality of life assessment should be used alongside pain levels at baseline and follow‐up. There are core outcome sets being developed that should be considered in future trials and reviews. </p> </li> <li> <p>Investigators of future trials should collect data on adjunct opioid pain control, as there is a nationwide push for reduced opioid pain management due to the ongoing opioid addiction crisis. </p> </li> <li> <p>Investigators of future trials should also avoid or reduce the potential sources of bias identified in this review, such as selection bias caused by differential attrition rates at follow‐up and information bias introduced by complete‐case analysis when the proportion of missing outcome data is substantial. </p> </li> <li> <p>Investigators should report outcomes by treatment arm both overall and within sex/gender and race/ethnicity subgroups of participants. </p> </li> <li> <p>Investigators should differentiate between abrasions with complications (e.g. rust rings) and abrasions without complications to increase the applicability of the evidence to difference patient groups. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015091-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015091-sec-0008"></div> <div class="table" id="CD015091-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical ophthalmic anesthetic compared with placebo or NSAID</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Topical ophthalmic anesthetic compared with placebo or NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patients or population:</b> corneal abrasion (post‐trauma or post‐surgical) </p> <p><b>Settings:</b> emergency department or ophthalmology surgery </p> <p><b>Intervention:</b> anesthetic (tetracaine, proparacaine, lidocaine) </p> <p><b>Comparison:</b> placebo or NSAID (diclofenac, artificial tears, saline) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Relative effect <b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with anesthetic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 24 hours</b><br/>Assessed with: VAS pain intensity </p> <p>0 to 10</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Lower is better.</p> <p>The original VAS was from 0 to 100 in <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>, which compared tetracaine 1% with placebo in post‐trauma participants. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 3.63 (SD 1.00)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 1.28 lower (0.80 to 1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/>(3 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> (see comment) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 0.11 (SD 0.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.04 lower (0.10 lower to 0.02 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>NSAID, post‐surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 2.09 (SD 1.77)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.82 higher (0.01 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 48 hours</b><br/>Assessed with: VAS pain intensity </p> <p>0 to 10</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Lower is better.</p> <p><a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> was excluded from the analysis due to missing data. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 0.81 (SD 1.46)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.41 higher (0.45 lower to 1.27 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 7.23 (SD 1.95)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 5.68 lower (4.98 lower to 6.38 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 72 hours</b><br/>Assessed with: VAS pain intensity </p> <p>0 to 10</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 0.2 (SD 0.83)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.49 higher (0.06 lower to 1.04 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower is better.</p> <p>Only <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a> reported pain outcomes beyond 48 hours (at 64 hours). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR &lt; 1 is better.</p> <p>Another post‐surgery trial (44 participants) reported no events in either arm.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> <p>(118 to 367)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.37 (0.78 to 2.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221</p> <p>(3 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> <p>(2 to 510)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14 (0.01 to 2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of participants with complications at longest time point</b> </p> <p>Up to 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR &lt; 1 is better.</p> <p>Two post‐surgical trials (75 participants) and one post‐trauma trial (33 participants) reported no events in either arm. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> <p>(15 to 355)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.13 (0.23 to 5.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> <p>(3 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> <p>(1 to 356)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.00 (0.38 to 128.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**The corresponding risk was the absolute risk (number of events divided by number of participants in the intervention group). The 95% CI was calculated using a binomial distribution. </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NSAID:</b> nonsteroidal anti‐inflammatory drug; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analog scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for serious risk of bias (−2 levels).<br/><sup>b</sup>Downgraded for imprecision (−1 level).<br/><sup>c</sup>Downgraded for indirectness (−1 level).<br/><sup>d</sup>Downgraded for risk of bias (−1 level).<br/><sup>e</sup>Downgraded for inconsistency (−1 level).<br/><sup>f</sup>Downgraded for extreme imprecision (−2 levels). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015091-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical ophthalmic anesthetic plus NSAID compared with placebo</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Topical ophthalmic anesthetic plus NSAID compared with placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patients or population:</b> corneal abrasion (post‐surgical) </p> <p><b>Settings:</b> ophthalmology surgery </p> <p><b>Intervention:</b> anesthetic with NSAID (proparacaine plus diclofenac) </p> <p><b>Comparison:</b> placebo (artificial tears) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Relative effect <b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with anesthetic plus NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 24 hours</b><br/>VAS (scale 0 to 10) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 8.08 (SD 2.28)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 5.72 lower (4.09 lower to 7.35 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 48 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 72 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/>(8 to 570) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/>(0.04 to 2.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &lt; 1 is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with complications at longest time point</b> </p> <p>Up to 1 week</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No adverse events reported in either arm.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &lt; 1 is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NSAID:</b> nonsteroidal anti‐inflammatory; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analog scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (−1 level). <br/><sup>b</sup>Downgraded for extreme imprecision (−2 levels). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015091-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015091-sec-0009"></div> <section id="CD015091-sec-0010"> <h3 class="title" id="CD015091-sec-0010">Description of the condition</h3> <p>Corneal abrasions (also known as corneal epithelial defects) are lamellar losses of the corneal epithelium, the superficial, regenerative, squamous barrier of the cornea (<a href="./references#CD015091-bbs2-0073" title="NishidaT , SaikaS , MorishigeN . Cornea and sclera: anatomy and physiology. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Nishida 2022</a>). Etiologies of abrasions include accidental trauma (mechanical, chemical, or phototoxic), ocular surgery, corneal dryness, exposure (inadequate eyelid coverage of the cornea), neurotrophic disease, ocular inflammation, infection, as well as a variety of other intrinsic ocular pathologies (<a href="./references#CD015091-bbs2-0073" title="NishidaT , SaikaS , MorishigeN . Cornea and sclera: anatomy and physiology. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Nishida 2022</a>). Corneal abrasion is a common emergency, representing about 13% of eye‐related emergency department visits in the United States (<a href="./references#CD015091-bbs2-0039" title="ChannaR , ZafarSN , CannerJK , HaringRS , SchneiderEB , FriedmanDS . Epidemiology of eye-related emergency department visits. JAMA Ophthalmology2016;134(3):312-9.">Channa 2016</a>; <a href="./references#CD015091-bbs2-0094" title="VaziriK , SchwartzSG , Flynn HW Jr, KishorKS , MoshfeghiAA . Eye-related emergency department visits in the United States, 2010. Ophthalmology2016;123(4):917-9.">Vaziri 2016</a>), with an estimated annual incidence of 3 per 1000 persons and a roughly two‐to‐one male predominance according to the National Ambulatory Medical Care Survey (NAMCS) (<a href="./references#CD015091-bbs2-0068" title="McGwin G Jr, XieA , OwsleyC . Rate of eye injury in the United States. Archives of Ophthalmology2005;123(7):970-6.">McGwin 2005</a>). Globally an estimated 55 million eye injuries occur each year, with 750,000 requiring hospitalization (<a href="./references#CD015091-bbs2-0074" title="NégrelAD , ThyleforsB . The global impact of eye injuries. Ophthalmic Epidemiology1998;5(3):143-69.">Négrel 1998</a>). </p> <p>Abrasions resulting from trauma may inoculate the eye with foreign matter and microbial organisms, leading to corneal infection. Symptoms of a corneal abrasion include intense pain, photophobia, redness, and tearing. Depending on the healthcare setting, corneal abrasions may be diagnosed and initially treated by primary care physicians, emergency medicine providers, or eye care specialists (<a href="./references#CD015091-bbs2-0027" title="AhmedF , HouseRJ , FeldmanBH . Corneal abrasions and corneal foreign bodies. Primary Care2015;42(3):363-75.">Ahmed 2015</a>). On clinical examination, corneal epithelial defects are best visualized by instilling fluorescein dye into the tear film, which adheres to bare stroma (but not intact epithelium), and emits a green fluorescence when illuminated with cobalt‐blue filtered light (<a href="./references#CD015091-bbs2-0067" title="MartonyiCL . Slit lamp examination and photography. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Martonyi 2022</a>). In an emergency setting, an examination is performed with a slit lamp biomicroscope or penlight to identify other complicating factors such as microbial infection (manifested as a corneal infiltrate), corneal laceration (deep injury beyond the corneal epithelium), or the presence of a foreign body (<a href="./references#CD015091-bbs2-0052" title="HamillMB . Mechanical injury. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Hamill 2022</a>). </p> <p>In contrast to trauma, the creation of a corneal epithelial defect is the intended consequence of many commonly performed ocular surgeries, including photorefractive keratectomy (PRK, a laser refractive procedure), superficial keratectomy (removal of anterior corneal lesions), and the epithelium‐off variations of corneal cross‐linking (a treatment for keratoconus). Unlike accidental trauma, abrasions created in the setting of ocular surgery derive benefit from a sterile field. Often, adjunctive treatments such as intraoperative topical mitomycin‐C (an anti‐metabolite) and postoperative steroids are used to reduce postoperative inflammation and scarring. Bandage contact lenses are typically applied for patient comfort after these types of procedures and are removed when the cornea re‐epithelializes (<a href="./references#CD015091-bbs2-0043" title="ChuckRS , JacobsDS , LeeJK , AfshariNA , VitaleS , ShenTT , et al. Refractive errors &amp; refractive surgery Preferred Practice Pattern®. Ophthalmology2018;125(1):P1-P104.">Chuck 2018</a>; <a href="./references#CD015091-bbs2-0049" title="Garcia-FerrerFJ , AkpekEK , AmescuaG , FaridM , LinA , RheeMK , et al. Corneal Ectasia Preferred Practice Pattern®. Ophthalmology2019;126(1):P170-215.">Garcia‐Ferrer 2019</a>). </p> <p>The human cornea is one of the most densely innervated tissues, with an estimated density of approximately 7000 nerve terminals per square millimeter (<a href="./references#CD015091-bbs2-0073" title="NishidaT , SaikaS , MorishigeN . Cornea and sclera: anatomy and physiology. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Nishida 2022</a>). Approximately 20% of corneal nociceptors are mechanoreceptors that generate acute pain (<a href="./references#CD015091-bbs2-0088" title="ShaheenBS , BakirM , JainS . Corneal nerves in health and disease. Survey of Ophthalmology2014;59(3):263-85.">Shaheen 2014</a>). Regardless of the cause of a corneal abrasion, the dense network of sensory nerve endings in the cornea may result in intense eye pain until the corneal epithelial defect is healed (<a href="./references#CD015091-bbs2-0066" title="MarfurtCF , CoxJ , DeekS , DvorscakL . Anatomy of the human corneal innervation. Experimental Eye Research2010;90(4):478-92.">Marfurt 2010</a>; <a href="./references#CD015091-bbs2-0073" title="NishidaT , SaikaS , MorishigeN . Cornea and sclera: anatomy and physiology. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Nishida 2022</a>). In a healthy eye, most such defects heal fully in 24 to 48 hours by peripheral migration of sheets of epithelial cells, ultimately derived from the limbal epithelial stem cells (<a href="./references#CD015091-bbs2-0052" title="HamillMB . Mechanical injury. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Hamill 2022</a>); topical antibiotic is almost always prescribed to prevent infection. Although healing often occurs without permanent damage to the cornea, potential complications include recurrent corneal erosions, infectious keratitis, corneal scarring, thinning of the corneal stroma, or corneal perforation. These events may require intensive medical or surgical management and can lead to vision loss or loss of the eye. The mainstays of treatment for a corneal abrasion are infection prophylaxis and pain control, coupled with close outpatient follow‐up (<a href="./references#CD015091-bbs2-0052" title="HamillMB . Mechanical injury. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Hamill 2022</a>). </p> </section> <section id="CD015091-sec-0011"> <h3 class="title" id="CD015091-sec-0011">Description of the intervention</h3> <p>Although it is standard practice to prescribe topical antimicrobial drops or ointments for corneal abrasions as prophylaxis against infection, there is variability in practice patterns for treatment of the pain (<a href="./references#CD015091-bbs2-0052" title="HamillMB . Mechanical injury. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Hamill 2022</a>; <a href="./references#CD015091-bbs2-0085" title="SabriK , PanditJC , ThallerVT , EvansNM , CrockerGR . Current management of corneal abrasions: evidence based practice?British Journal of Ophthalmology1997;81(12):1116-7.">Sabri 1997</a>). Ointments, bandage contact lenses, and patching of the eye closed under a gauze pad may decrease discomfort by reducing direct exposure of the defect and minimizing the mechanical irritation caused by repeated eyelid movement. It is theorized, however, that patching and bandage contact lenses could potentiate corneal infections by decreasing the cycling of tears over the ocular surface, thereby trapping microbes and impeding the action of host immune factors and antimicrobial medications (<a href="./references#CD015091-bbs2-0052" title="HamillMB . Mechanical injury. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Hamill 2022</a>). A Cochrane Review found that patching may not aid with healing or pain control. No conclusions, however, could be drawn about the relative risk of complications (<a href="./references#CD015091-bbs2-0065" title="LimCH , TurnerA , LimBX . Patching for corneal abrasion. Cochrane Database of Systematic Reviews2016, Issue 7. Art. No: CD004764. [DOI: 10.1002/14651858.CD004764.pub3]">Lim 2016</a>). Bandage contact lenses are another modality for ameliorating pain through barrier coverage while allowing for blinking, normal cosmesis, and the ability to see. In the setting of ocular surface surgeries, such as corneal cross‐linking or PRK, the placement of a bandage contact lens is standard practice. Although the clinical efficacy and safety of bandage contact lenses have been established to some degree in the setting of traumatic corneal abrasions (<a href="./references#CD015091-bbs2-0071" title="MenghiniM , KnechtPB , KaufmannC , KovacsR , WatsonSL , LandauK , et al. Treatment of traumatic corneal abrasions: a three-arm, prospective, randomized study. Ophthalmic Research2013;50(1):13-8.">Menghini 2013</a>; <a href="./references#CD015091-bbs2-0092" title="VandorselaerT , YoussfiH , Caspers-Valu LE , DumontP , VauthierL . Treatment of traumatic corneal abrasion with contact lens associated with topical nonsteroid anti-inflammatory agent (NSAID) and antibiotic: a safe, effective and comfortable solution [Traitement des érosions cornéennes traumatiques par l'association d'une lentille de contact, d'un collyre anti-inflammatoire non stéroïdien (AINS) et d'un collyre antibiotique: solution sûre, efficace et confortable]. Journal Français D'Ophtalmologie2001;24(10):1025-33.">Vandorselaer 2001</a>), it is well‐known that extended contact lens wear increases the risk of infection and, therefore, contact lens use may be discouraged for corneal abrasions judged to be at high risk for microbial inoculation (<a href="./references#CD015091-bbs2-0052" title="HamillMB . Mechanical injury. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Hamill 2022</a>; <a href="./references#CD015091-bbs2-0080" title="PoggioEC , GlynnRJ , ScheinOD , SeddonJM , ShannonMJ , ScardinoVA , et al. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. New England Journal of Medicine1989;321(12):779-83.">Poggio 1989</a>; <a href="./references#CD015091-bbs2-0086" title="ScheinOD , GlynnRJ , PoggioEC , SeddonJM , KenyonKR . The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. New England Journal of Medicine1989;321(12):773-8.">Schein 1989</a>). </p> <p>In contrast to systemic analgesics such as oral acetaminophen, nonsteroidal anti‐inflammatory drugs (NSAIDs), gabapentin, and opioids for abrasions, topical pharmacologic analgesics have the most direct, local effect on ocular pain with limited systemic side effects. Classes of topical ophthalmic treatments for corneal pain include NSAIDs (ketorolac, diclofenac, indomethacin, bromfenac, flurbiprofen, nepafenac) as well as amide and ester analgesics (tetracaine, proparacaine, lidocaine). Amide and ester anesthetics act to inhibit electrical conduction on axons by blocking sodium channels on the inner wall of the cell membrane (<a href="./references#CD015091-bbs2-0063" title="LevineLM , BrarVS , GoldsteinMH , KahanaA , KatowitzMR , LawSK , et al. Ocular pharmacokinetics. In: CantorLB , RapuanoCJ , CioffiGA , editors(s). Basic and Clinical Science Course: Fundamental and Principles of Ophthalmology. American Academy of Ophthalmology, 2017.">Levine 2017</a>). The duration of action of these medications is approximately 20 to 30 minutes, and they therefore require frequent dosing for use in the outpatient setting to be effective (<a href="./references#CD015091-bbs2-0063" title="LevineLM , BrarVS , GoldsteinMH , KahanaA , KatowitzMR , LawSK , et al. Ocular pharmacokinetics. In: CantorLB , RapuanoCJ , CioffiGA , editors(s). Basic and Clinical Science Course: Fundamental and Principles of Ophthalmology. American Academy of Ophthalmology, 2017.">Levine 2017</a>). Analgesic intervention may be administered as an adjuvant to other treatments for corneal analgesia including bandage contact lenses, ointments, patching, topical NSAIDs, or oral analgesics. Here we study the efficacy and safety of topical amide and ester anesthetics for corneal abrasions. </p> </section> <section id="CD015091-sec-0012"> <h3 class="title" id="CD015091-sec-0012">How the intervention might work</h3> <p>Topical ophthalmic amide and ester medications act directly on sensory corneal nerve endings to relieve pain. In the clinical setting, these medications provide immediate relief to ocular surface pain to permit a thorough eye exam. Likewise, the immediate effectiveness of these medications also allows for excellent analgesia for a wide variety of ocular procedures (<a href="./references#CD015091-bbs2-0063" title="LevineLM , BrarVS , GoldsteinMH , KahanaA , KatowitzMR , LawSK , et al. Ocular pharmacokinetics. In: CantorLB , RapuanoCJ , CioffiGA , editors(s). Basic and Clinical Science Course: Fundamental and Principles of Ophthalmology. American Academy of Ophthalmology, 2017.">Levine 2017</a>). These analgesic properties may be therapeutic over several days of outpatient use as a corneal epithelial defect heals. Accordingly, a recent systematic review found that topical NSAIDs for corneal abrasions significantly reduced pain and oral analgesia use without a difference in complications compared with control (<a href="./references#CD015091-bbs2-0102" title="YuCW , KirubarajanA , YauM , ArmstrongD , JohnsonDE . Topical pain control for corneal abrasions: a systematic review and meta-analysis. Academic Emergency Medicine2021;28(8):890-908. [DOI: 10.1111/acem.14222]">Yu 2021</a>). </p> </section> <section id="CD015091-sec-0013"> <h3 class="title" id="CD015091-sec-0013">Why it is important to do this review</h3> <p>Despite potential analgesic benefits from outpatient use of topical ophthalmic amides and esters, their use has become a topic of great controversy. Multiple published case reports and series have identified severe ocular complications associated with the outpatient use of topical anesthetic medications (<a href="./references#CD015091-bbs2-0028" title="AksoyA , BaşkanAM , AslanL , AslankurtM . Topical proparacaine abuse resulting in evisceration. BMJ Case Reports2013;2013:bcr2013009539.">Aksoy 2013</a>; <a href="./references#CD015091-bbs2-0031" title="AnsariH , GaribaldiDC , JunAS . Anaesthetic abuse keratopathy as a manifestation of ocular Munchausen's syndrome. Clinical and Experimental Ophthalmology2006;34(1):81-3. [DOI: 10.1111/j.1442-9071.2006.01152.x]">Ansari 2006</a>; <a href="./references#CD015091-bbs2-0032" title="ArdjomandN , FaschingerC , Haller-SchoberEM , ScarpatettiM , FaulbornJ . A clinico-pathological case report of necrotizing ulcerating keratopathy due to topical anaesthetic abuse [Nekrotisierende ulzerierende Keratopathie nach Lokalanasthetikamissbrauch Ein klinisch-pathologischer Fallbericht]. Ophthalmologe2002;99(11):872-5. [DOI: 10.1007/s00347-002-0623-z]">Ardjomand 2002</a>; <a href="./references#CD015091-bbs2-0040" title="ChenHT , ChenKH , HsuWM . Toxic keratopathy associated with abuse of low-dose anesthetic: a case report. Cornea2004;23(5):527-9. [DOI: 10.1097/01.ico.0000114127.63670.06]">Chen 2004</a>; <a href="./references#CD015091-bbs2-0041" title="ChernKC , MeislerDM , WilhelmusKR , JonesDB , SternGA , LowderCY . Corneal anesthetic abuse and candida keratitis. Ophthalmology1996;103(1):37-40.">Chern 1996</a>; <a href="./references#CD015091-bbs2-0046" title="DornicDI , ThomasJM , LassJH . Topical diclofenac sodium in the management of anesthetic abuse keratopathy. American Journal of Ophthalmology1998;125(5):719-21. [DOI: 10.1016/s0002-9394(98)00009-9]">Dornic 1998</a>; <a href="./references#CD015091-bbs2-0047" title="EpsteinDL , PatonD . Keratitis from misuse of corneal anesthetics. New England Journal of Medicine1968;279(8):396-9.">Epstein 1968</a>; <a href="./references#CD015091-bbs2-0057" title="KatsimprisJM , SarantoulakouM , KordelouA , PetkouD , PetropoulosIK . Clinical findings in patients with topical anaesthetic abuse keratitis: a report of five cases. Klinische Monatsblatter für Augenheilkunde2007;224(4):303-8. [DOI: 10.1055/s-2007-962933]">Katsimpris 2007</a>; <a href="./references#CD015091-bbs2-0058" title="KhakshoorH , MoshirfarM , SimpsonRG , GharaeeH , VejdaniAH , ChristiansenSM , et al. Anesthetic keratopathy presenting as bilateral Mooren-like ulcers. Clinical Ophthalmology2012;6:1719-22.">Khakshoor 2012</a>; <a href="./references#CD015091-bbs2-0059" title="KimJY , ChoiYS , LeeJH . Keratitis from corneal anesthetic abuse after photorefractive keratectomy. Journal of Cataract and Refractive Surgery1997;23(3):447-9. [DOI: 10.1016/s0886-3350(97)80192-7]">Kim 1997</a>; <a href="./references#CD015091-bbs2-0060" title="LeeJK , StarkWJ . Anesthetic keratopathy after photorefractive keratectomy. Journal of Cataract and Refractive Surgery2008;34(10):1803-5.">Lee 2008</a>; <a href="./references#CD015091-bbs2-0078" title="PharmakakisNM , KatsimprisJM , MelachrinouMP , KoliopoulosJX . Corneal complications following abuse of topical anesthetics. European Journal of Ophthalmology2002;12(5):373-8. [DOI: 10.1177/112067210201200505]">Pharmakakis 2002</a>; <a href="./references#CD015091-bbs2-0084" title="RosenwasserGO , HollandS , PflugfelderSC , LugoM , HeidemannDG , CulbertsonWW , et al. Topical anesthetic abuse. Ophthalmology1990;97(8):967-72.">Rosenwasser 1990</a>; <a href="./references#CD015091-bbs2-0093" title="VargaJH , RubinfeldRS , WolfTC , StutzmanRD , PeeleKA , CliffordWS , et al. Topical anesthetic abuse ring keratitis: report of four cases. Cornea1997;16(4):424-9.">Varga 1997</a>; <a href="./references#CD015091-bbs2-0097" title="WebberSK , SuttonGL , LawlessMA , RogersCM . Ring keratitis from topical anaesthetic misuse. Australian and New Zealand Journal of Ophthalmology1999;27(6):440-2. [DOI: 10.1046/j.1440-1606.1999.00246.x]">Webber 1999</a>; <a href="./references#CD015091-bbs2-0099" title="WillisWE , LaibsonPR . Corneal complications of topical anesthetic abuse. Canadian Journal of Ophthalmology1970;5(3):239-43.">Willis 1970</a>; <a href="./references#CD015091-bbs2-0100" title="WuH , HuY , ShiXR , XuF , JiangCY , HuangR , et al. Keratopathy due to ophthalmic drug abuse with corneal melting and perforation presenting as Mooren-like ulcer: A case report. Experimental and Therapeutic Medicine2016;12(1):343-6. [DOI: 10.3892/etm.2016.3296]">Wu 2016</a>; <a href="./references#CD015091-bbs2-0101" title="YagciA , BozkurtB , EgrilmezS , PalamarM , OzturkBT , PekelH . Topical anesthetic abuse keratopathy: a commonly overlooked health care problem. Cornea2011;30(5):571-5. [DOI: 10.1097/ico.0b013e3182000af9]">Yagci 2011</a>). Reported complications include infection, corneal scarring, perforations, and severe ocular morbidities requiring evisceration or enucleation. In fact, topical anesthetic abuse seems to be a distinct entity with characteristic features such as persistent epithelial defects, corneal stromal ring infiltrates, disproportionate pain, and concurrent substance abuse disorder (<a href="./references#CD015091-bbs2-0084" title="RosenwasserGO , HollandS , PflugfelderSC , LugoM , HeidemannDG , CulbertsonWW , et al. Topical anesthetic abuse. Ophthalmology1990;97(8):967-72.">Rosenwasser 1990</a>). A person abusing one of these topical medications may have obtained it in a surreptitious way or may not admit to their use, making the diagnosis of abuse and treatment challenging. In support of these concerns, an intact corneal sensation from the trigeminal nerve is integral to the feedback loop that heals and maintains the ocular surface (<a href="./references#CD015091-bbs2-0088" title="ShaheenBS , BakirM , JainS . Corneal nerves in health and disease. Survey of Ophthalmology2014;59(3):263-85.">Shaheen 2014</a>). People with neurotrophic corneas (decreased or absent corneal sensation often from insults to the trigeminal nerve from herpes simplex virus, varicella‐zoster virus, ocular surgery, neurosurgery, diabetes, or other causes) have chronically high rates of dry eye, non‐healing epithelial defects, microbial keratitis, corneal scarring, corneal thinning, and corneal perforation (<a href="./references#CD015091-bbs2-0038" title="ChangBH , EwaldMD , GroosEB . Neurotrophic keratitis. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Chang 2022</a>). Although the pain response to a corneal abrasion is severe, nociception is part of a protective sensory mechanism that includes increased tear production, the blink reflex, and the stimulation of growth factors important for healing (<a href="./references#CD015091-bbs2-0038" title="ChangBH , EwaldMD , GroosEB . Neurotrophic keratitis. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Chang 2022</a>). The pain itself may serve as a harbinger of a complication, prompting timely presentation to medical care. In addition to interrupting the neural feedback loop, there is evidence that anesthetic medications may be directly cytotoxic to the corneal epithelium, although the full mechanism remains to be studied (<a href="./references#CD015091-bbs2-0033" title="BoljkaM , KolarG , VidensekJ . Toxic side effects of local anaesthetics on the human cornea. British Journal of Ophthalmology1994;78(5):386-9.">Boljka 1994</a>; <a href="./references#CD015091-bbs2-0076" title="ParsonsMR . Factitious keratoconjunctivitis. In: MannisMJ , HollandEJ , editors(s). Cornea: Fundamentals, Diagnosis, and Management. 5th edition. Amsterdam (NL): Elsevier, 2022.">Parsons 2022</a>; <a href="./references#CD015091-bbs2-0077" title="PeymanGA , RahimyMH , FernandesML . Effects of morphine on corneal sensitivity and epithelial wound healing: implications for topical ophthalmic analgesia. British Journal of Ophthalmology1994;78(2):138-41.">Peyman 1994</a>). Embracing many of these sentiments, a survey of 75 corneal specialists found universal opposition to the outpatient use of topical anesthetics (<a href="./references#CD015091-bbs2-0061" title="LeeMD , DriverTH , SeitzmanGD . Cornea specialists do not recommend routine usage of topical anesthetics for corneal abrasions. Annals of Emergency Medicine2019;74(3):463-6.">Lee 2019</a>). However, there is a paucity of studies both designed and sufficiently powered to establish a causal relationship between outpatient topical anesthetic use and ocular complications. Although the collective body of case reports and series indicates a syndrome of topical anesthetic abuse (often with devastating consequences), it is unclear whether a strict prohibition is warranted, or whether these medications can be safely administered in a controlled and limited fashion in order to relieve suffering, in the same manner that topical steroids are prescribed for pain and inflammation despite potential for abuse and adverse events. Given the prevalence of both traumatic and surgically created corneal abrasions, an evidence‐based analgesic strategy for corneal epithelial defects will have broad implications for clinical care. Our goal is to review outcome data from randomized controlled trials (RCTs) of topical amide and ester anesthetics for the efficacy of analgesia and safety for corneal epithelial defects resulting from both trauma and ocular surface surgery. Since particularly devastating complications may be rare, pooling data from multiple studies provides more statistical power to estimate the benefits and risks of use more accurately and precisely than any single RCT. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015091-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015091-sec-0014"></div> <p>To assess the effectiveness and safety of topical ophthalmic anesthetics compared with placebo or other treatments in persons with corneal abrasions. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015091-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015091-sec-0015"></div> <section id="CD015091-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015091-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs) in this review. We included all eligible trials irrespective of their publication status. We planned to include within‐person trials, where eyes had been allocated randomly to the intervention and comparator, but none were found. </p> </section> <section id="CD015091-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials that enrolled participants of all ages who had corneal abrasions within 48 hours of presentation, and from varying causes, including accidental trauma and ophthalmic surgery<i>.</i> </p> </section> <section id="CD015091-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared topical ophthalmic anesthetics (amide or ester class) with a non‐amide or non‐ester control group (either placebo, non‐treatment, or alternative treatment). We also included trials in which topical anesthetics with an NSAID were compared with a control group (see <a href="#CD015091-sec-0117">Differences between protocol and review</a>). We excluded trials in which participants were given topical anesthetics only once after trauma‐ or surgery‐induced abrasion because of negligible clinical benefits or harms associated with the transient pharmacological effects of topical anesthetics. </p> </section> <section id="CD015091-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD015091-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD015091-sec-0022"> <h6 class="title">Critical outcomes</h6> <p> <ul id="CD015091-list-0001"> <li> <p>Pain control: change in participant‐reported ocular pain as measured using a pain scale that is continuous (e.g. 0 to 10 cm visual analog scale, VAS) or discrete (e.g. numerical rating scale 0 = "no pain" through 10 = "worst pain imaginable") from baseline to 24 hours, 48 hours, and 72 hours after treatment initiation. When the change scores were not available, we used pain scores measured at the above‐mentioned follow‐up time points. </p> </li> <li> <p>Epithelial healing: proportion of participants without complete resolution of epithelial defects by 24 to 72 hours. </p> </li> <li> <p>Complications: proportion of participants with adverse events (e.g. microbial keratitis or stromal infiltration, corneal stromal thinning, corneal perforation, surgical interventions) reported at the longest follow‐up time of the study. Complications that suggest abuse would be nonhealing epithelial defect, stromal infiltration, thinning, or perforation. The last two would be seen most likely after more than a week of frequent use of topical anesthetic. </p> </li> </ul> </p> </section> </section> <section id="CD015091-sec-0023"> <h5 class="title">Secondary outcomes</h5> <section id="CD015091-sec-0024"> <h6 class="title">Important outcomes</h6> <p> <ul id="CD015091-list-0002"> <li> <p>Treatment failure: proportions of participants who required rescue oral analgesics by 72 hours after treatment initiation. </p> </li> <li> <p>Quality of life: mean changes in quality of life as measured by a validated instrument for health‐related or vision‐related quality of life, or functions of daily activity as quantified by the 7 or 12 Instrumental Activities of Daily Living checklist, as defined in the original study. We planned to use data from the longest follow‐up time of the study. When the change scores were not available, we planned to use mean scores instead. </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD015091-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015091-sec-0026"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist searched the following electronic databases for potentially eligible RCTs and controlled clinical trials. There were no restrictions based on language or year of publication. The search was performed on 19 February 2022 and updated on 10 February 2023. Search details are provided in the specified appendices. </p> <p> <ul id="CD015091-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (2023, Issue 2) (<a href="./appendices#CD015091-sec-0103">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (All) (1946 to 10 February 2023) (<a href="./appendices#CD015091-sec-0104">Appendix 2</a>). </p> </li> <li> <p>Embase.com (Elsevier) (1947 to 10 February 2023) (<a href="./appendices#CD015091-sec-0105">Appendix 3</a>). </p> </li> <li> <p>PubMed (1948 to 10 February 2023) (<a href="./appendices#CD015091-sec-0106">Appendix 4</a>). </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to 10 February 2023) (<a href="./appendices#CD015091-sec-0107">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (<a href="./appendices#CD015091-sec-0108">Appendix 6</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>) (<a href="./appendices#CD015091-sec-0109">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD015091-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of studies that were included following full‐text screening. We also searched the reference lists of systematic reviews and guidelines for additional trials missed by the electronic searches. We did not handsearch specific journals or conference proceedings as many eyes and vision conferences are included in Embase. </p> </section> </section> <section id="CD015091-sec-0028"> <h3 class="title" id="CD015091-sec-0028">Data collection and analysis</h3> <section id="CD015091-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The Information Specialist performed electronic searches of the selected databases and removed duplicates. We worked in pairs (MS, KC, CI, SL, LL, IK) and independently screened the titles and abstracts resulting from the searches using the web‐based software <a href="./references#CD015091-bbs2-0044" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 28 July 2021. Available at covidence.org.">Covidence</a>. We resolved disagreements by discussion. We noted the number of citations considered not relevant in the selection of studies flow diagram (<a href="#CD015091-fig-0001">Figure 1</a>). We obtained full‐text copies of reports from trials judged to be potentially relevant by either review author. We corresponded with study investigators to clarify study eligibility, as appropriate. For trial registration records and meeting abstracts with no full‐text report, we contacted the study investigators for desired information about study methods and any outcome data that were available. Whenever study investigators did not respond within two weeks, we proceeded with the information available. </p> <div class="figure" id="CD015091-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD015091-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>Working in pairs, review authors (MS, KC, CI, SL, LL, IK) independently assessed the full‐text copies of reports for inclusion by applying the <a href="#CD015091-sec-0016">Criteria for considering studies for this review</a>. We resolved disagreements by discussion. For non‐English study reports, we used Google Translate for the initial translation of the Methods and Results sections of the report, which was sufficient to determine eligibility; we therefore did not enlist human translation. We were not masked to the names of the authors, institutions, or journal publications. </p> <p>We listed all studies excluded during full‐text screening and provided a justification for exclusion (see <a href="./references#CD015091-sec-0120" title="">Characteristics of excluded studies</a>). </p> </section> <section id="CD015091-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We piloted the data extraction form developed by Cochrane Eyes and Vision (CEV) in <a href="./references#CD015091-bbs2-0044" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 28 July 2021. Available at covidence.org.">Covidence</a>. We worked in pairs of review authors (MS, KC, CI, SL, LL, IK) to independently extract data. We resolved discrepancies through discussion. </p> <p>We contacted trial investigators for desired data that had not been reported and allowed two weeks for a response before proceeding with the available data. All data were imported directly into <a href="./references#CD015091-bbs2-0083" title="Review Manager Web (RevMan Web). Version 5.2.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web</a> by one author (LL) and one author (SL) verified the accuracy of the data imported. </p> <p>For multi‐arm studies, we used data relevant to our intervention and comparator groups, taking care not to double‐count or omit participants. We planned, when two randomly allocated trial arms (interventions or comparators) contained relevant data, to combine data from them using the calculator within <a href="./references#CD015091-bbs2-0083" title="Review Manager Web (RevMan Web). Version 5.2.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web</a>. Where data transformation was required (e.g. standard errors (SEs) from standard deviations (SDs), extracting data presented only in graphs or figures) we followed the guidance outlined in Chapter 5 and Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015091-bbs2-0055" title="HigginsJPT , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022a</a>; <a href="./references#CD015091-bbs2-0064" title="LiT , HigginsJPT , DeeksJJ . Chapter 5: Collecting data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Li 2022</a>). We extracted data available only in graphs or figures using browser‐based data extraction software (<a href="./references#CD015091-bbs2-0098" title="WebPlotDigitizer. Version 4.5. Rohatgi A, accessed 20 October 2022. Available from: automeris.io/WebPlotDigitizer.">WebPlotDigitizer</a>). </p> </section> <section id="CD015091-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the potential risk of bias in each included study using Cochrane's RoB 2 tool, as outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015091-bbs2-0056" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022b</a>). Working in pairs, review authors (MS, KC, CI, SL, LL, IK) assessed the risk of bias independently using the RoB 2 Excel tool (22 August 2019 version for individually randomized, parallel‐group trials; available from <a href="https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2?authuser=0" target="_blank">riskofbiasinfo.org</a>). We compared judgments and resolved disagreements by discussion. We assessed bias for the 'intention‐to‐treat effect' for the efficacy outcome of pain control by 48 hours and the safety outcome of complications at the longest follow‐up time. </p> <p>We considered and assessed risk of bias in the following domains:</p> <p> <ul id="CD015091-list-0004"> <li> <p>bias due to the randomization process;</p> </li> <li> <p>bias due to deviations from the intended intervention;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome; and</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>Based on these five domains, we assigned an overall risk of bias judgment of 'high', 'some concerns', or 'low' risk of bias. </p> </section> <section id="CD015091-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We referred to the guidance outlined in Chapters 9 and 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015091-bbs2-0045" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>; <a href="./references#CD015091-bbs2-0069" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV . Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">McKenzie 2022</a>). We calculated the risk ratio (RR) and 95% confidence intervals (95% CIs) for dichotomous outcomes (proportion of participants without full epithelial healing at 24 to 72 hours). We calculated the risk difference (RD) and 95% CI for dichotomous outcomes when one or more trials had zero events in both arms. We calculated the mean difference (MD) and 95% CIs for continuous outcomes (changes in pain scores from baseline to 24, 48, and 72 hours after treatment; risk of adverse events at longest time point). We had planned to calculate the standardized mean difference (SMD) and 95% CIs for continuous outcomes measured using different scales (e.g. mean change in quality of life or activities of daily living). Where possible, we checked for the skewness of continuous data (<a href="./references#CD015091-bbs2-0030" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200.">Altman 1996</a>). </p> </section> <section id="CD015091-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>Where variations on RCTs were included, we referred to Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015091-bbs2-0054" title="HigginsJPT , EldridgeS , LiT . Chapter 23: Including variants on randomized trials. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021c</a>). When both eyes of participants had been allocated to the same or different interventions, we extracted the results that accounted for the correlation between eyes. Whenever the investigators of a primary study had failed to consider the correlation between two eyes, or it was unclear whether they had, we excluded those studies in the sensitivity analysis. </p> </section> <section id="CD015091-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We requested missing data from study authors and allowed two weeks for a response before proceeding with the available data. We calculated missing standard deviations using P values, based on the methods outlined in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015091-bbs2-0055" title="HigginsJPT , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022a</a>). We did not impute missing data ourselves. When outcome data based on intention‐to‐treat (ITT) analysis were not available, we collected and combined, whenever feasible, data as reported by authors of the included trials based on either per‐protocol or complete‐case analysis. Either approach assumed that some outcome data were missing at random; we assessed whether this assumption was reasonable by collecting data from each included trial on the number of participants excluded or lost to follow‐up and reasons for loss to follow‐up by treatment group when reported. This information was also used to assess potential risk of bias in individual trials (<a href="./references#CD015091-bbs2-0056" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022b</a>). </p> </section> <section id="CD015091-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined the overall characteristics of the studies and participants (see <a href="./references#CD015091-sec-0119" title="">Characteristics of included studies</a>); in particular, we looked at the type of participants and types of interventions, to assess the extent to which the studies were similar enough to make pooling study results in meta‐analyses sensible. </p> <p>We examined the forest plots of study results for consistency of effect estimates from individual studies; in particular, we considered the size and direction of effects and overlap of confidence intervals. We calculated the I<sup>2</sup> statistic, which is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) (<a href="./references#CD015091-bbs2-0053" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>). We considered I<sup>2</sup> values over 75% to indicate considerable heterogeneity but also considered Chi<sup>2</sup> and P values (<a href="./references#CD015091-bbs2-0045" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD015091-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned that, when there were 10 trials or more included in a meta‐analysis, we would construct funnel plots and consider tests for asymmetry to assess small study effects, which may be due to publication bias and other factors, according to Chapter 13 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015091-bbs2-0075" title="PageMJ , HigginsJPT , SterneJAC . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Page 2022</a>)<i>.</i> Because there were only nine included trials that varied in the interventions and outcomes reported, we did not construct funnel plots. We examined selective reporting of results during the assessment of potential risk of bias. </p> </section> <section id="CD015091-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We referred to Chapters 9 and 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for data synthesis (<a href="./references#CD015091-bbs2-0045" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>; <a href="./references#CD015091-bbs2-0069" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV . Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">McKenzie 2022</a>). We pooled data using random‐effects models in <a href="./references#CD015091-bbs2-0083" title="Review Manager Web (RevMan Web). Version 5.2.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web</a> when there were three or more trials reported on the same outcome. When data were sparse (fewer than three trials), we used a fixed‐effect model for meta‐analysis of outcomes. </p> <p>Whenever there was substantial heterogeneity among individual study effect estimates, such that a combined result may not provide a good summary of the individual trial results, we did not pool the data but described the pattern of the individual study results. When there was evidence of statistical heterogeneity but all the effect estimates were in the same direction, such that a combined estimate would seem to provide a good summary of the individual trial results, we combined the data. </p> </section> <section id="CD015091-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analysis if there were more than 10 trials (<a href="./references#CD015091-bbs2-0103" title="SulewskiM , IfantidesC , Liu S-H, LeslieL , KuoIC . Topical ophthalmic anesthetics for corneal abrasions. Cochrane Database of Systematic Reviews2022, Issue 5. Art. No: CD015091. [DOI: 10.1002/14651858.CD015091]">Sulewski 2022</a>). Although only nine trials were included, we performed subgroup analysis on 'pain control', 'epithelial healing', or both, by the following covariates: </p> <p> <ul id="CD015091-list-0005"> <li> <p>etiology of corneal abrasion: ocular surgery or trauma;</p> </li> <li> <p>exposure to intervention medications:</p> <ul id="CD015091-list-0006"> <li> <p>duration of use (24 to 48 hours versus 48 hours or longer);</p> </li> <li> <p>concentration of anesthetic (diluted versus standard concentration).</p> </li> </ul> </li> </ul> </p> <p>We were unable to analyze outcomes by gender or race as there were minimal demographic data in the study reports and no outcomes reported by treatment arm within the demographic subgroups. We did not perform subgroup analysis by frequency of use because all included trials had a frequency of use ≥ 4 times per day (see <a href="#CD015091-sec-0117">Differences between protocol and review</a>). </p> </section> <section id="CD015091-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis by:</p> <p> <ul id="CD015091-list-0007"> <li> <p>excluding studies judged to be at an overall high risk of bias;</p> </li> <li> <p>excluding within‐person studies that had not addressed the correlation of outcomes in pairs of eyes when reporting the trial results. </p> </li> </ul> </p> </section> <section id="CD015091-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared summary of findings tables to present relative and absolute risks estimated from the included studies based on interventions compared (<a href="./references#CD015091-bbs2-0087" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Schünemann 2022</a>). Working in pairs, review authors (MS, KC, CI, SL, LL, IK) independently graded the overall certainty of the evidence, resolving discrepancies by discussion, for the following efficacy and safety outcomes using the GRADE classification (<a href="./references#CD015091-bbs2-0087" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Schünemann 2022</a>): </p> <p> <ul id="CD015091-list-0008"> <li> <p>Efficacy outcomes: changes in mean participant‐reported ocular pain from baseline to 24 hours, 48 hours, and 72 hours after treatment initiation. </p> </li> <li> <p>Safety outcomes:</p> <ul id="CD015091-list-0009"> <li> <p>proportion of participants without complete resolution of epithelial defects by 24 to 72 hours; </p> </li> <li> <p>proportion of participants with adverse events reported at the longest follow‐up time of the study. </p> </li> </ul> </li> </ul> </p> <p>We considered the following five elements when deciding to downgrade the certainty of the body of evidence from a high to a low level: </p> <p> <ul id="CD015091-list-0010"> <li> <p>high risk of bias among included studies;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>unexplained heterogeneity or inconsistency of results;</p> </li> <li> <p>imprecision of results; or</p> </li> <li> <p>high likelihood of publication bias.</p> </li> </ul> </p> <p>We applied study‐level risk of bias assessments, based on responses to signaling questions in domains 1 to 3 of the RoB 2 tool, to provide judgment on risk of bias when we graded outcomes that we did not choose for complete RoB 2 assessment. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015091-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015091-sec-0041"></div> <section id="CD015091-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD015091-sec-0043"> <h4 class="title">Results of the search</h4> <p>The Information Specialist found 7980 records in the electronic databases and 263 records in trial registries on 19 February 2022. The search was run again on 10 February 2023, which retrieved a further 906 records from electronic databases (date limit January 2022 to 10 February 2023) and 319 records from trial registries. We did not identify any eligible studies through supplemental searches. After removing duplicates, we screened 7641 records from which we excluded 7602 records. We then assessed 39 full‐text articles for eligibility and included nine trials (21 records) in the current review (<a href="#CD015091-fig-0001">Figure 1</a>). We labeled one study (<a href="./references#CD015091-bbs2-0026" title="AseffA , ValdezJ , VargasJ , VidaurriJ . Wound healing and patient discomfort after excimer photorefractive keratectomy with topical diclofenac vs topic tetracaine. Investigative Ophthalmology and Visual Science1997;38:ARVO Abstract 2465. ">Aseff 1997</a>) as 'awaiting classification' because of incomplete data reported in the meeting abstract. We excluded 16 studies (17 records) and listed the reason for exclusion in the <a href="./references#CD015091-sec-0120" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD015091-sec-0044"> <h4 class="title">Included studies</h4> <section id="CD015091-sec-0045"> <h5 class="title">Types of trials</h5> <p>We give details of the nine included RCTs in the <a href="./references#CD015091-sec-0119" title="">Characteristics of included studies</a> table and summarize them in <a href="#CD015091-tbl-0003">Table 1</a>. The trials span the years 1994 to 2021, and they were conducted in multiple settings and locations. The median study length was seven days (interquartile range (IQR) 7 to 14 days; nine RCTs). The median study length was 11 days (IQR 7 to 18 days; 4 RCTs) for post‐trauma trials and seven days (IQR 3 to 7 days; 5 RCTs) for post‐surgical trials. The median anesthetic treatment duration was 24 hours (IQR 24 to 168 hours; nine RCTs). The median treatment duration was 36 hours (IQR 24 to 78 hours; four RCTs) for post‐trauma trials and 24 hours (IQR 24 to 168 hours; five RCTs) for post‐surgical trials. </p> <div class="table" id="CD015091-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Etiology</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention(s)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison(s)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Co‐intervention(s)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. participants randomized/analyzed, intervention arm</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. participants randomized/analyzed, control arm</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention duration</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Note</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ball 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proparacaine 0.05%</p> <p>2 to 4 drops, as needed, for 7 days, max dispensed 40 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops</p> <p>(color and smell‐ matched)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: gatifloxacin, 1 drop every 2 hours, for 7 days<br/>OA: 325 mg acetaminophen with 30 mg of codeine, 1 to 2 tablets every 4 hours if needed, for 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lim 1999</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) Proparacaine 0.05%<br/>2) Diclofenac 0.1% + proparacaine 0.05% </p> <p>1 drop every 4 hours for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> <p>(Tears Natural)</p> <p>1 drop every 4 hours for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: ofloxacine, every 6 hours, for 1 week<br/>OA: mefenamic acid, as needed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) 15/15<br/>2) 15/15 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 of 7 treatment arms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Montard 1999</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 1% every 30 minutes for 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1% every 4 hours for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: ofloxacine, every 6 hours, for 1 week<br/>OA: mefenamic acid, as needed<br/>Other: BCLs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oksuz 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pterygium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lidocaine 2%<sup>c</sup> </p> <p>1 mL every hour for 3 hours, starting 1 hour postop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears<sup>c</sup> </p> <p>(Thilo‐Tears Jelly)</p> <p>1 mL every hour for 3 hours, starting 1 hour postop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: NR<br/>OA: none<br/>Other: patched </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shahinian 1997</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada and US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proparacaine 0.05%</p> <p>1 drop 4 times a day for 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> <p>(Hypotears)</p> <p>1 drop 4 times a day for 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: 0.3% tobramycin and 0.1% dexamethasone, 4 times a day, over 1 week<br/>OA: acetaminophen and hydrocodone bitartrate, as needed, over 1 week<br/>Topical: topical diclofenac 0.1%, 4 times a day, for the first 48 hours<br/>Other: BCLs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 eyes/25 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 eyes/23 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shipman 2021</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 0.5%</p> <p>1 drop every 30 minutes as needed for 24 hours, max dispensed 2 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> <p>(Systane)</p> <p>1 drop every 30 minutes as needed for 24 hours, max dispensed 2 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: polymyxin B sulfate/trimethoprim sulfate, 2 drops every 4 hours, max 24 hours<br/>OA: hydrocodone 7.5 mg/acetaminophen 325 mg, 1 to 2 tablets as needed every 6 hours, max 12 tablets </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ting 2009</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 0.4%</p> <p>1 drop every hour as needed for 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops 0.9%</p> <p>1 drop every hour as needed for 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: topical antibiotics (unspecified)<sup>a</sup><br/>OA: oral analgesics (unspecified) as needed for eye pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 to 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Verma 1995</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 1%<sup>d</sup> </p> <p>1 drop every 30 minutes during waking hours for 24 hours, max dispensed 40 drops</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops<sup>d</sup> </p> <p>(physiologic saline)</p> <p>1 drop every 30 minutes during waking hours for 24 hours, max dispensed 40 drops</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: chloramphenicol 0.5%, topical, 1 drop every 6 hours, over 1 week<br/>OA: co‐proxamol, 2 tablets every 8 hours, over 2 days<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Waldman 2014</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 1% as needed, up to every 30 minutes for 24 hours, max dispensed 1.5 mL (50 drops) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops 0.9% as needed, up to every 30 minutes for 24 hours, max dispensed 1.5 mL (50 drops) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: preservative‐free chloramphenicol antibiotics 1%, topical ointment<br/>OA: paracetamol 500 mg, 2 tablets at 08:00, 12:00, 16:00, 20:00, oral, over 24 hours<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AB:</b> topical antibiotics; <b>BCLs:</b> bandage contact lenses; <b>NR:</b> not reported; <b>OA:</b> oral anesthetic; <b>PRK:</b> photorefractive keratectomy<br/><sup>a</sup>Not all participants received antibiotics (8/22 participants in the tetracaine group and 8/18 in the saline group received antibiotics).<br/><sup>b</sup>The study prescribed oral anesthetic to prevent breakthrough pain.<br/><sup>c</sup>Prescribed at 1, 2, and 3 hours postop, inpatient setting. Not taken on an as‐needed basis.<br/><sup>d</sup>Prescribed at a specific schedule. Not taken on an as‐needed basis. </p> </div> </div> <p>Of the nine RCTs, four (44%) were conducted in the emergency department setting; three of these were single‐center trials conducted in New Zealand (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), Australia (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>), and the United States (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>). <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> included two tertiary care emergency departments in Canada. Five RCTs (56%) were in ophthalmology surgical settings; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a> had two study sites, one in Canada and in the United States, while the other four RCTs were single‐center trials based in the United Kingdom (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>), Turkey (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>), France (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>), and South Korea (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>). Except for <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>, which enrolled participants following pterygium surgery, all surgical trials enrolled patients who were status post photorefractive keratectomy (PRK). </p> <p>The reporting of funding/sponsors varied; five trials did not have a statement regarding study funding, one reported there was no funding (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), and two stated partial support for authors from a foundation (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). None of the trials reported industry funding. Five trials reported no conflict of interest among trial investigators; the author of one trial was a patent holder for the intervention (<a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>), and reports from the other trials did not include a disclosure statement. </p> <p>All nine included trials had parallel‐group designs. Eight RCTs had two treatment arms, while <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> had seven. Eight trials randomized participants to treatment and analyzed data from one study eye. <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a> randomized post‐PRK participants to treatments (N = 34); some participants had both eyes enrolled as study eyes, whereas others had a single study eye (N = 48 eyes). Four trials reported an a priori power calculation for the primary outcome of the trial; one stated the sample size for statistical significance without further detail (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>), and the remaining four trials did not state whether sample size calculations had been performed. Additionally, <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> reported the power calculation for a secondary outcome. Four trials had associated trial registration records, one had been prospectively registered (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>), and three had been registered after the specified start date of participant enrollment (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). </p> </section> <section id="CD015091-sec-0046"> <h5 class="title">Types of participants</h5> <p>The nine included trials enrolled a total of 626 participants. Three of the seven treatment arms, one comparison and two separate interventions, of <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> were eligible for inclusion in this review (45/105 participants). We included in this review a total of 556 participants, with a median number of 45 participants per study (IQR 44 to 74). </p> <p>Five trials described 242 participants (256 eyes) with post‐surgical corneal defects: four from PRK (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>) and one from pterygium surgery (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). Four trials analyzed abrasions of traumatic etiology in a total of 314 participants (314 eyes) (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). The majority of abrasions involved corneal foreign bodies (47%, 148 eyes) or direct trauma (19%, 61 eyes). </p> <p>One eye of each participant had been treated and followed except in one trial, in which both eyes were allocated to the same treatment for four participants (eight eyes) who had bilateral surgery on the same day (<a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). It is unclear whether this method of assignment was used for second eyes of participants who had sequential surgery on separate days. </p> <p>Baseline characteristics of participants varied by age, gender, and ethnicity. One trial did not report the gender of the participants (<a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). Three of the eight trials that reported the participant gender reported numbers in the overall trial but not within individual treatment groups (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). For example, <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> reported that 71% of trial participants were women (75/105) but did not report gender by treatment arm. Among these eight trials, a higher proportion of women was seen in trials that had examined iatrogenic corneal abrasions from refractive or pterygium surgery (60%, 166/278; four RCTs) compared with trials of participants seen in emergency departments for corneal abrasions (21%, 65/314; four RCTs). </p> <p>None of the trials reported racial demographics. One trial conducted in New Zealand reported ethnicity of participants, with 59% (69/116) 'European', 7% (8/116) 'Maori', 2% (2/116) 'Other', and 32% (37/116) 'Not Reported' (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). </p> <p>One trial did not report the age of participants (<a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). Of the eight trials that had reported participants’ ages at baseline, all participants were 18 years or older with one exception: <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> enrolled one 17‐year‐old participant. <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> also had the widest age range (17 to 74 years old). Seven trials reported either a mean or median age for participants, ranging from 27.8 to 47.9 years old. </p> </section> <section id="CD015091-sec-0047"> <h5 class="title">Types of interventions</h5> <p>The nine included trials evaluated three of the commonly used topical anesthetics, of which types and concentrations varied: proparacaine (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>), tetracaine (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), and lidocaine (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). One study tested the amide anesthetic lidocaine 2% (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). Two ester anesthetics of various concentrations were tested in the other trials: tetracaine (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> at 1%; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a> at 0.5%; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a> at 0.4%) and proparacaine diluted from commercially available 0.5% to 0.05% (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> was a multi‐arm trial that tested both proparacaine 0.05% alone and its combination with topical diclofenac 0.1%. </p> <p>Four trials enrolled post‐trauma patients who were sent home from the emergency department with topical anesthetics of varying concentration, frequency, duration, and total amount dispensed for self‐administration (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). In <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>, investigators prescribed tetracaine 1%, dosed as often as every 30 minutes for 24 hours (1.5 mL total volume dispensed). In <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>, they prescribed tetracaine 0.5%, one drop every 30 minutes as needed for 24 hours (2 mL total volume dispensed). In <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>, they prescribed tetracaine 0.4%, one drop every hour as needed for 48 hours (1.5 mL total volume dispensed). In <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>, they prescribed proparacaine 0.05%, two to four drops as needed for seven days (40 mL total volume dispensed). The authors stated no minimum time interval between doses "allowing patients unlimited use of the study drug" (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>). </p> <p>The other five trials enrolled patients following ophthalmic surgery that had caused a corneal epithelial defect (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). In <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>, starting one hour after pterygium surgery, participants were administered lidocaine 2% hydrochloride gel, 1 mL every hour for three hours prior to hospital discharge. In <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>, surgeons prescribed proparacaine 0.05%, one drop four times per day. In <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>, they prescribed tetracaine 1%, one drop every 30 minutes "during waking hours" for 24 hours (40 drops total dispensed). In <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>, they prescribed tetracaine 1%, every 30 minutes for 24 hours. In <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>, they prescribed one group proparacaine 0.05%, one drop every four hours for seven days. The same dosing was used for the diclofenac 0.1% plus proparacaine 0.05% (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>). </p> <p>Eight of the included trials compared topical anesthetics to placebo treatment, which included saline (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), artificial tears (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>), and a "colour‐ and smell‐matched" placebo, likely vehicle (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>). The only trial that used an active comparator was <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>, in which the investigators compared tetracaine 1% with topical diclofenac 0.1%. Among the four trials that enrolled post‐trauma patients (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a> was the only trial that had used artificial tears whereas the other three trials used saline as the comparator. In contrast, among the four trials that enrolled post‐surgical patients (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>), <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a> was the only trial that used "physiologic saline" as the comparator. The other three trials used other brands of artificial tears; in <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a> artificial tears in gel form were used. In all included trials, these placebo treatments were prescribed at the same frequency and duration as the respective study's topical anesthetic treatment arm. The only trial with different frequency and duration between treatment arms was <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>, in which investigators prescribed tetracaine 1% every 30 minutes for 24 hours but allowed diclofenac 0.1% to be instilled every four hours for three days. </p> <p>Oral analgesics were prescribed in all but one trial (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). In two trials, oral analgesics were dosed on a schedule: two tablets of co‐proxamol (dextropropoxyphene 32.5 mg and paracetamol 325 mg) every eight hours for two days (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>) and two tablets of 500 mg paracetamol at 08:00, 12:00, 16:00, and 20:00 over 24 hours (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). Six of the RCTs prescribed various analgesics on an 'as‐needed' basis for breakthrough pain, including paracetamol‐noramidopyrine (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>), acetaminophen and codeine (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>), acetaminophen and hydrocodone (<a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>), and mefenamic acid (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>); one study did not specify the analgesic (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). </p> <p>The five surgical trials had different pre‐, peri‐, and postoperative protocols (see <a href="./references#CD015091-sec-0119" title="">Characteristics of included studies</a> for details). In two trials, bandage contact lenses were placed in post‐surgical eyes (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). All surgical eyes had occlusive patching in <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>. Topical antibiotics were used in all RCTs except for <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>. A variety of antibiotics were prescribed: chloramphenicol 0.5% (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>), chloramphenicol 1% (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), ofloxacin 0.3% (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>), and unspecified concentrations of ofloxacin (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>), polymyxin B sulfate/trimethoprim sulfate (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>), and gatifloxacin (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>). One study used a combination of 0.3% tobramycin and 0.1% dexamethasone (<a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). Antibiotics were not prescribed equally within and between groups in one study; 8/22 participants in the tetracaine group and 8/18 in the saline group received antibiotics (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). </p> </section> <section id="CD015091-sec-0048"> <h5 class="title">Critical outcomes</h5> <section id="CD015091-sec-0049"> <h6 class="title">Pain control from baseline to 24 hours, 48 hours, and 72 hours after treatment initiation</h6> <p>All included nine trials assessed pain intensity using pain scoring systems where higher numbers represented higher pain intensity. Eight trials used a VAS, with two using 0‐ to 100‐point continuous scales (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>) and the others using a 0‐ to 10‐point continuous scales. <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a> used a 0‐ to 10‐point continuous pain intensity scale but did not specify whether the instrument was a visual analog or numeric scale. </p> <p>Baseline pain was recorded in two of the four trials of participants with traumatic corneal injuries (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). Some participants reported no pain at baseline and were analyzed in a mixed‐model to account for multiple measurements (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a> did not report baseline pain and <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> only reported the change score. In post‐surgical trials, the baseline pain following surgery was not reported. <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a> only reported the mean pain before taking study drops. The earliest time point at which postoperative pain was reported was one hour (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>), four hours (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>), or the end of the day (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>). In <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>, the baseline pain could not be extracted from the presented figure. </p> <p>A clinically important difference in the VAS measurement of pain intensity was defined in three trials: 16 mm (SD 25 mm) on a 100 mm VAS (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), 2 cm (SD 2 cm) on a 10 cm VAS (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>), and 1.5 cm (SD 2.5 cm) on a 10 cm VAS (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>). <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> cited two observational studies that had validated the use of the VAS to assess acute (primarily abdominal) pain in the emergency department setting as the basis for selecting 16 mm. <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> used an informal survey of attending emergency department physicians. <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a> did not report how 1.5 cm was selected as a clinically important difference. <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a> defined 3 cm as an acceptable level of pain on a 10 cm VAS but did not specify how this number was chosen. </p> <p>We included data from six trials for pain outcomes reported at up to 24, 48, and 72 hours. <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> reported the mean pain intensity and P values comparing artificial tears versus anesthetic groups on day one but not on days two and three. We used the P value to determine the standard deviation for day one in order to include the data at 24 hours following the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015091-bbs2-0055" title="HigginsJPT , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022a</a>). <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a> reported pain scores at four, seven, and 10 hours postoperatively, but we included only the 10‐hour follow‐up value in the analysis of pain control from baseline to 24 hours. <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a> reported the pain profile at 24 hours based on a single factor analysis to extrapolate pain during sleeping hours. </p> <p>The mean and standard error were extracted from figures for 24‐, 48‐, and 64‐hour time points reported in <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>. <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> used a mixed‐model to account for multiple measurements over the 48 hours and separately reported the mean difference for follow‐up durations of 24 and 48 hours. <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a> recorded the change in scores from pre‐ and two minutes post‐instillation of study drops and reported the overall pain rating at 24 to 48 hours follow‐up. </p> <p>We did not include pain score data from three trials in the meta‐analysis (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>), because the timeframe of the trial results was outside the pre‐specified time windows or the trial results were reported as period averages. The authors of <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a> reported averaged pain scores over the first postoperative week as documented by participants immediately before and one minute after applying the study eye drops (used as needed). Similarly, <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> reported the aggregated median change scores from all recorded pre‐ and five minutes post‐use of study drops over seven days. <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a> reported the total pain burden over 36 hours. </p> </section> <section id="CD015091-sec-0050"> <h6 class="title">Epithelial healing by 24 to 72 hours</h6> <p>Epithelial healing was assessed by slit lamp biomicroscopy in the majority of trials (67%; 6/9) (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>); two other trials used digitized and computer‐assisted measurements (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). One trial stated only that "the ophthalmologist was directed to identify signs of delayed wound healing" (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>). Despite the variations in measurements of epithelial healing performed among the trials, we were not able to use all reported data in our analysis of this outcome. Three trials reported mean time to epithelial healing, but proportions of eyes with epithelial healing at 24 to 72 hours could not be derived (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> assessed eyes at three, five, and seven days after injury and reported, "no ocular complications or evidence of delayed wound healing in either group." </p> </section> <section id="CD015091-sec-0051"> <h6 class="title">Complications reported at the longest follow‐up time</h6> <p>The median study length of seven days (post‐surgical trials) and 11 days (post‐trauma trials) gives an indication of the longest follow‐up. Methods of assessing complications included clinical assessment, such as slit lamp biomicroscopy, by an ophthalmologist or emergency medicine physician (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). Other methods of assessing complications included the following: eliciting complaints from participants using a list of qualifying complications (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), eliciting complaints from participants without a list, judgment by an ophthalmologist who was asked to identify complications including any that appeared to be related to the initial injury or the use of study medications (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>), or no report of method used (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>). These subjective assessments were conducted at the time of clinical assessment, during telephone interview (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), or in response to text messages (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). Most trials did not provide details on complications such as microbial keratitis or stromal infiltration, corneal stromal thinning, corneal perforation, or surgical interventions. Four trials reported specific adverse events (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). Three other trials stated only that there had been no adverse events (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). The remaining two trials provided no information about complications (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). </p> </section> </section> <section id="CD015091-sec-0052"> <h5 class="title">Important outcomes</h5> <section id="CD015091-sec-0053"> <h6 class="title">Treatment failure at 72 hours after treatment initiation</h6> <p>Investigators of one study reported the number of eyes that had required analgesia for breakthrough pain, from 24 hours to two weeks (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). Reports from no other trial provided data for this outcome because our protocol specified the proportion of participants (or eyes) that were treatment failures rather than the amount of analgesia taken over the study period (e.g. median number of hydrocodone tablets over 48 hours). In addition, one indication of treatment failure as defined by our protocol was the use of rescue oral analgesics for pain not alleviated by topical anesthetic medication. Therefore, trials in which oral analgesics were prescribed to prevent breakthrough pain were not included in the analysis (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). </p> <p><a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a> did not describe the use of oral analgesics. <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> assessed the number of oral analgesics used but did not report the results. Four of the included trials reported the amount of oral analgesia taken over the study period as a continuous measure, so we did not include these in the analysis (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>). </p> </section> <section id="CD015091-sec-0054"> <h6 class="title">Quality of life</h6> <p>None of the included trials assessed health‐related, vision‐related, or function‐related quality of life outcome assessments. </p> </section> </section> </section> <section id="CD015091-sec-0055"> <h4 class="title">Excluded studies</h4> <p>We documented reasons for exclusion of 16 studies in the table of <a href="./references#CD015091-sec-0120" title="">Characteristics of excluded studies</a>. We translated five non‐English articles using Google Translate; the original languages were French (<a href="./references#CD015091-bbs2-0018" title="HenrotteJ , WeekersJF . Clinical study of corneal lesions due to local and prolonged application of anesthetics [Etude clinique des lésions cornéennes dues à l'application locale et prolongée d'anesthésiques]. Archives d’Ophtalmologie et Revue Générale d’Ophtalmologie1972;32(6):449-56. ">Henrotte 1972</a>), Portuguese (<a href="./references#CD015091-bbs2-0016" title="FerreiraAA , HortaAMS , GomesMI , LuzCAB . Analgesia postoperative in ophthalmology: subconjuntival bupivacaine [Analgesia pós-operatória em oftalmologia: bupivacaína subconjuntival]. Arquivos do Instituto Penido Burnier1992;34(2):106-9. ">Ferreira 1992</a>), Italian (<a href="./references#CD015091-bbs2-0017" title="FilipponeC , MolinelliG . Comparative trials of corneal anesthesia, using instillation of an 0.5-percent solution of Rec 7-0518 as compared with a 4-percent solution of cocaine. Clinico-statistical study [Sperimentazione comparativa sull'anestesia corneale da instillazione tra una soluzione di Rec 7-0518 allo 0,5 percent ed una soluzione di cocaina al 4-percent. Studio clinico-statistico]. Annali di Ottalmologia e Clinica Oculistica1967;93(2):212-21. ">Filippone 1967</a>), and German (<a href="./references#CD015091-bbs2-0023" title="SteinerL . Clinical experimental studies of the effects of various local anesthetics on the cornea [Klinisch-experimentelle Untersuchungen über die Wirkung einiger Oberflächenanästhetika auf die Hornhaut]. Klinische Monatsblätter für Augenheilkunde1966;148(4):536-40. ">Steiner 1966</a>; <a href="./references#CD015091-bbs2-0025" title="WeindlerJ . Cocaine eye drops or lidocaine-gel in addition to intra-chamber anesthesia in clear-corneal cataract surgery [Cocain-Augentropfen oder Lidocain-Gel zur Ergänzung der intrakameralen Anaesthesie bei der Clear-Cornea-Kataraktchirurgie?]. Ophthalmologe2001;98(Suppl 1):S189. ">Weindler 2001</a>). Further translation was not required to determine whether the trial was eligible for inclusion. We contacted the investigators of two trials that had registration records to inquire about trial status and data availability; one confirmed the trial had been halted, and data were not available (<a href="./references#CD015091-bbs2-0020" title="NCT02483897. Effect of tetracaine on pain management and corneal healing in patients with acute corneal abrasion. clinicaltrials.gov/show/NCT02483897 (first received 29 June 2015). ">NCT02483897</a>); the other investigator stated that the trial had never been initiated and had never enrolled participants (<a href="./references#CD015091-bbs2-0021" title="NCT02771392. Treatment of corneal abrasions with topical tetracaine: an evaluation of safety and efficacy. clinicaltrials.gov/show/NCT02771392 (first received 13 May 2016). ">NCT02771392</a>). For another study, we requested information regarding randomization but did not receive any response (<a href="./references#CD015091-bbs2-0015" title="CherryPM . The treatment of pain following excimer laser photorefractive keratectomy: additive effect of local anesthetic drops, topical diclofenac, and bandage soft contact. Ophthalmic Surgery Lasers1996;27(5 Suppl):S477-80. ">Cherry 1996</a>). Based on other published reports referenced in <a href="./references#CD015091-bbs2-0015" title="CherryPM . The treatment of pain following excimer laser photorefractive keratectomy: additive effect of local anesthetic drops, topical diclofenac, and bandage soft contact. Ophthalmic Surgery Lasers1996;27(5 Suppl):S477-80. ">Cherry 1996</a>, we determined that the study did not meet our eligibility criteria. Of the 16 excluded studies, eight were excluded for ineligible populations, four were excluded for ineligible study designs, three had ineligible interventions, and one had an ineligible comparison group. </p> <section id="CD015091-sec-0056"> <h5 class="title">Studies awaiting classification</h5> <p>We did not have enough information to confidently include or exclude a study reported only in a meeting abstract (<a href="./references#CD015091-bbs2-0026" title="AseffA , ValdezJ , VargasJ , VidaurriJ . Wound healing and patient discomfort after excimer photorefractive keratectomy with topical diclofenac vs topic tetracaine. Investigative Ophthalmology and Visual Science1997;38:ARVO Abstract 2465. ">Aseff 1997</a>). Multiple contact attempts for all listed authors of the abstract were unsuccessful. </p> </section> </section> </section> <section id="CD015091-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias for two outcomes: 1) the mean participant‐reported ocular pain from baseline to 48 hours (<a href="#CD015091-fig-0002">Figure 2</a>), and 2) the proportion of participants with complications (<a href="#CD015091-fig-0003">Figure 3</a>). We assessed the risk of bias in two trials that reported the first outcome (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>), and seven trials for the second outcome (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). For the domain‐specific judgments, the domains for which we assessed trials to be at the highest risk of bias were missing outcome data or selective reporting of outcome data. </p> <div class="figure" id="CD015091-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias: Change in participant‐reported ocular pain from baseline to 48 hours" data-id="CD015091-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias: Change in participant‐reported ocular pain from baseline to 48 hours</p> </div> </div> </div> <div class="figure" id="CD015091-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias: Proportion of participants with complications at longest time point" data-id="CD015091-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias: Proportion of participants with complications at longest time point</p> </div> </div> </div> <section id="CD015091-sec-0058"> <h4 class="title">Domain 1 ‐ Bias arising from the randomization process</h4> <p>We judged five trials to have low risk of bias as they described methods of randomized sequence generation and methods to conceal allocation, such as the use of sealed, opaque envelopes (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>) and "research pharmacists not involved in the design or conduct of the study prepared identical, clear, minim packs" (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). Neither <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> nor <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a> described a method of allocation concealment, and few baseline characteristics of participants were provided. Therefore, we had some concerns about risk of bias for this domain. </p> </section> <section id="CD015091-sec-0059"> <h4 class="title">Domain 2 ‐ Bias arising from deviations from intended interventions</h4> <p>Two trials addressed the primary outcome of pain at 48 hours (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). We assessed one study as possessing low risk of bias because of deviations from intention‐to‐treat (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>). For <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>, we had some concerns about bias. </p> <p>For adverse events, we assessed the evidence from four trials as indicating low risk of bias arising from deviations from intended interventions (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). We had some concerns about two trials because of unclear post‐randomization exclusion of participants (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), no mention of adverse events (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>), and the potential unmasking of participants due to the burning sensation of tetracaine (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). We judged one study to have a high risk of bias because data were excluded for avoidable reasons, such as not having medication, not recording pain measurements, and loss to follow‐up (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>). </p> </section> <section id="CD015091-sec-0060"> <h4 class="title">Domain 3 ‐ Bias due to missing outcome data</h4> <p>Regarding pain control by 48 hours, we judged one study as having a low risk of bias because of few missing outcome data (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>), and one study as having high risk of bias because of differences in follow‐up rates between treatment groups (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). </p> <p>For adverse events at the longest follow‐up, we assessed three trials as having low risk of bias due to no missing data (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). We had some concerns about bias in one study because 20% of participants did not contribute adverse event data and the investigators did not provide any explanation (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>). We assessed three trials as possessing a high risk of bias because not all participants were required to follow up after 24 hours (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>), or had multiple follow‐up visits with varying attendance, and self‐reporting of adverse event data (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). There was substantial loss to follow‐up for the clinical assessment at the 48‐hour (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>) and one‐week (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>) time points. In <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>, all participants who missed clinic follow‐up were successfully contacted by other methods (telephone, text messaging). In <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>, there was still missing data for 32% of participants after similar use of text messaging. </p> </section> <section id="CD015091-sec-0061"> <h4 class="title">Domain 4 ‐ Bias in outcome measurement</h4> <p>For pain control by 48 hours, we assessed two included trials as having low risk of bias associated with measurement of the outcome (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). </p> <p>For collection of adverse events, we judged three trials as possessing low risk of bias (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). In two trials, there were some concerns about bias arising from examiners not being masked to treatment and sparse detail(s) of how adverse events were evaluated (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). We assessed two trials as having a high risk of bias for reasons such as disparity in the frequency of scheduled clinical assessments. In one study, delayed healing increased the frequency of assessment only for patients with incomplete healing (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). In the second study, the baseline and follow‐up assessments in the emergency department were not described in detail, for example by gross physical exam, slit lamp biomicroscopy, or fluorescein dye uptake as visualized by under cobalt blue light, and relied on self‐reporting of adverse events (which may have gone undetected in the anesthetic group) (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). </p> </section> <section id="CD015091-sec-0062"> <h4 class="title">Domain 5 ‐ Bias in selective reporting of outcome data</h4> <p>Concerning pain control by 48 hours, we assessed one study as having low risk of bias because all outcomes were reported (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>), and another study as having high risk of bias because reporting of results diverged from the statistical plan in the protocol (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>). </p> <p>For bias related to reporting adverse outcomes, we deemed two trials to have low risk of bias (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). We had some concerns about bias in four trials due to no study protocol being found or no definition of an adverse event (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>), multiple possible time points of measurement (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>), no data analysis plan, and multiple possible definitions used across the study (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>). We considered one study at high risk of bias due to having no statistical analysis plan, a large cohort of participants excluded in a post hoc fashion for an unexpected result (i.e. persistent rust rings), and multiple time points with different numbers of participants at each (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). </p> </section> <section id="CD015091-sec-0063"> <h4 class="title">Overall assessment of bias</h4> <p>In summary, for the outcome of pain control at 48 hours, we deemed one study to be at high risk of bias (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>), and another study to raise some concerns about risk of bias (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). For the outcome of adverse events at the last follow‐up time point, we judged one of the trials to be at low risk of bias, we had some concerns about risk of bias in one study, and we judged the remaining five trials to have high risk of bias. </p> </section> </section> <section id="CD015091-sec-0064"> <h3 class="title" id="CD015091-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD015091-tbl-0001"><b>Summary of findings 1</b> Topical ophthalmic anesthetic compared with placebo or NSAID</a>; <a href="./full#CD015091-tbl-0002"><b>Summary of findings 2</b> Topical ophthalmic anesthetic plus NSAID compared with placebo</a> </p> <p>We reported the effects of topical anesthetics in the following two comparisons: Comparison 1: Anesthetics alone versus placebo or NSAID (<a href="./full#CD015091-tbl-0001">summary of findings Table 1</a>); Comparison 2: Anesthetics plus NSAID versus placebo (<a href="./full#CD015091-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD015091-sec-0065"> <h4 class="title">Comparison 1: Anesthetics versus placebo or NSAID</h4> <section id="CD015091-sec-0066"> <h5 class="title">Critical outcomes</h5> <section id="CD015091-sec-0067"> <h6 class="title">Pain control from baseline to 24 hours after treatment initiation</h6> <p>Three post‐surgical trials (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>) and one post‐trauma trial (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>) comparing topical anesthetics with placebo reported pain control at this time point. One additional post‐surgical trial compared topical tetracaine with diclofenac (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>). </p> <p>The combined estimate for pain scores reported by post‐surgical participants at 24 hours suggested that when compared with placebo, topical anesthetics reduced pain by 1.28 points on a 10‐point scale (MD −1.28, 95% CI −1.76 to −0.80; 3 RCTs, 119 participants; <a href="#CD015091-fig-0004">Figure 4</a>) (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). The authors of <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> reported pain scores as model‐predicted values based on averaging multiple measurements over the first post‐intervention 24 hours. Based on the raw data provided by the author team, the single‐study estimate, converted from a 100‐point to a 10‐point scale, was derived from 76 participants (61% of 124 randomized) and showed no evidence of a difference in pain control by 24 hours (MD −0.04 points, 95% CI −0.10 to 0.02). </p> <div class="figure" id="CD015091-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.1 Change in participant‐reported ocular pain from baseline to 24 hours" data-id="CD015091-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.1 Change in participant‐reported ocular pain from baseline to 24 hours </p> </div> </div> </div> <p>The investigators of <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a> recruited 74 participants who had undergone PRK and reported this outcome by comparing topical tetracaine 1% (every 30 minutes for 24 hours) with diclofenac 0.1% (four times a day for three days). The single‐study estimate indicated an 0.82‐point higher pain score (on a 10‐point VAS) in the tetracaine group than in the diclofenac group (MD 0.82, 95% CI 0.01 to 1.63). We did not combine data across subgroups because of heterogeneity between them (I<sup>2</sup> = 93%). The overall level of certainty of the effect estimates based on the available evidence is very low because of high risk of bias (−2 levels) associated with incomplete data and imprecision (−1 level) from small sample sizes. </p> </section> <section id="CD015091-sec-0068"> <h6 class="title">Pain control from baseline to 48 hours after treatment initiation</h6> <p>One post‐surgical trial (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>) and two post‐trauma trials (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>) compared pain control by 48 hours for tetracaine versus placebo. We did not include <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> in this analysis given the substantial proportion of participants lost to follow‐up (and thus the risk of attrition bias); the data for only 43% of 124 randomized participants (tetracaine n = 26; saline n = 27) were reported, according to the information provided by the authors. </p> <p>The single post‐surgical trial reported 0.41‐point greater pain in the anesthetic group on a 10‐point scale, showing little to no effect on pain control compared with placebo (MD 0.41, 95% CI −0.45 to 1.27; 44 participants; <a href="#CD015091-fig-0005">Figure 5</a>) (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). The post‐trauma trial had an estimated mean difference of 5.68 points (on a 10‐point scale), indicating that there may be a large reduction in pain when comparing topical anesthesia versus placebo (MD ‐5.68, 95% CI ‐6.38 to ‐4.98; 111 participants; <a href="#CD015091-fig-0005">Figure 5</a>) (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>), which is different in direction and magnitude from the estimate from <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>. We did not pool these two trials for analysis because of substantial statistical heterogeneity (I² = 99%). The overall certainty of evidence was very low because of high risk of bias (−2 levels), due to missing data and selective outcome reporting, imprecision (−1 level), and inconsistency (−1 level). </p> <div class="figure" id="CD015091-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.2 Change in participant‐reported ocular pain from baseline to 48 hours" data-id="CD015091-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.2 Change in participant‐reported ocular pain from baseline to 48 hours </p> </div> </div> </div> </section> <section id="CD015091-sec-0069"> <h6 class="title">Pain control from baseline to 72 hours after treatment initiation</h6> <p>Based on data from one post‐surgical trial, topical anesthetics had little to no effect on self‐reported pain measured on a 10‐point VAS at 64 hours (MD 0.49 point, 95% CI −0.06 to 1.04; 44 participants; <a href="./references#CD015091-fig-0010" title="">Analysis 1.3</a>) (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). The overall certainty of evidence was very low because of risk of bias (−1 level), indirectness (−1 level), and imprecision (−1 level) from the small sample size. </p> </section> <section id="CD015091-sec-0070"> <h6 class="title">Pain control reported at other time points</h6> <p>One trial reported the mean cumulative pain score of 12 assessments over 36 hours for 55% (12/22) of tetracaine participants and 36% (9/25) of saline participants initially randomized (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). The topical anesthetic group had a lower mean cumulative pain score of 404 (SD 75) compared with 629 (SD 172) for saline on a 100‐point scale. </p> <p>Another two trials reported a seven‐day mean or median change in pain scores immediately before and after the use of study drops (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> reported the seven‐day median change in pain score five minutes after using the study drops. The proparacaine group had a median improvement of 3.9 points on a 10‐point scale (IQR 1.5 to 5.1; n = 15) compared with a median of 0.6 points (IQR 0.2 to 2.0; n = 18) in the placebo group (P = 0.007, reported in <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>). <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a> reported the seven‐day mean change in pain score one minute after using study drops for 45 of 48 eyes. The proparacaine group had a larger decrease in mean pain (mean −1.75 points, SD 0.69) compared with placebo (mean −0.85 points, SD 0.98) on a 10‐point VAS (P &lt; 0.002, reported in <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>). </p> </section> <section id="CD015091-sec-0071"> <h6 class="title">Epithelial healing by 24 to 72 hours</h6> <p>Five trials reported proportions of eyes without complete resolution of epithelial defects by 24 to 72 hours for anesthetics compared with placebo (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). Three post‐trauma trials formed a subgroup with different concentrations of tetracaine; results of meta‐analysis for this subgroup provided no evidence of a difference in epithelial healing when tetracaine was compared with placebo (RR 1.37, 95% CI 0.78 to 2.42; 221 participants; I² = 0%; <a href="#CD015091-fig-0006">Figure 6</a>) (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). There were insufficient data to explore any dose‐response relationship. </p> <div class="figure" id="CD015091-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.5 Proportion of eyes without complete resolution of epithelial defects by 24 to 72 hours" data-id="CD015091-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.5 Proportion of eyes without complete resolution of epithelial defects by 24 to 72 hours </p> </div> </div> </div> <p>In one post‐surgical trial, all participants' corneal abrasions had healed by 24 to 72 hours (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>); there was no evidence of a difference in effect between treatment groups in the other post‐surgical trial (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>) (RR 0.14, 95% CI 0.01 to 2.55; 30 participants; <a href="#CD015091-fig-0006">Figure 6</a>). </p> <p>We calculated the risk difference (RD) to include the post‐surgical trial <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>, in which epithelial healing had occurred in all eyes in both treatment groups. Analysis by the duration of anesthetic use showed no evidence of differences in the resolution of epithelial defects across trial settings (post‐surgical or post‐trauma) or treatment duration (<a href="./references#CD015091-fig-0013" title="">Analysis 1.6</a>). However, the evidence is of very low certainty because of risk of bias (−1 level), inconsistency (−1 level), and imprecision (−1 level). </p> </section> <section id="CD015091-sec-0072"> <h6 class="title">Complications reported by the longest follow‐up time</h6> <p>Seven trials reported the number or proportion of participants with complications by the longest follow‐up time for topical anesthetics compared with placebo (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). </p> <p>In the post‐surgical trials, no complications were reported in either treatment group for two trials: <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> up to one week and <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a> up to 48 hours. In <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>, the longest follow‐up was six months, although adverse events were reported at the week one postoperative clinical assessment. In <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>, at one week, three participants in the tetracaine group experienced gritty sensation in the eye (n = 1), blurred vision (n = 1), and heaping of the epithelium (n = 1) compared with zero complications in the placebo group. The 95% CI of the estimated RR, despite crossing the line of no effect, is very asymmetric in favor of placebo (RR 7.00, 95% CI 0.38 to 128.02; 44 participants; <a href="#CD015091-fig-0007">Figure 7</a>). The authors also stated that 20% of the trial participants experienced nausea and vomiting attributed to the oral analgesia (paracetamol/dextropropoxyphene), but no episodes were reported by the treatment group (<a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). </p> <div class="figure" id="CD015091-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.7 Proportion of individuals/eyes with complications at furthest time point" data-id="CD015091-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.7 Proportion of individuals/eyes with complications at furthest time point </p> </div> </div> </div> <p>Among the post‐trauma trials, <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> reported no adverse events in either treatment arm. <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a> reported complications at the two‐week phone interview. Meta‐analysis of complications reported from the other three post‐trauma trials provided an estimated RR of 1.13 (95% CI 0.23 to 5.46; 242, 3 RCTs; <a href="#CD015091-fig-0007">Figure 7</a>) (<a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). In the anesthetic group, the adverse events included infiltrate (n = 1), opaque scar (n = 1), worsening of the corneal abrasion (n = 2), and visual problems (n = 1). In the placebo group, the adverse events included recurrent corneal erosion (n = 1), worsening corneal abrasion (n = 2), residual foreign body (n = 2), uncontrolled pain (n = 2), and persistent redness and blurred vision or visual problems (n = 4). </p> <p>We performed a separate analysis, including trials without events in either arm (see <a href="#CD015091-sec-0117">Differences between protocol and review</a>). In <a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>, the authors stated, "we did not observe any corneal epithelial or ocular surface complications in either group" up to 48 hours. At one week, <a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a> reported "no ocular complications" and <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> stated "no keratitis was observed." The combined risk difference (RD) of 0.01 (95% CI −0.03 to 0.05; 7 RCTs, 394 participants; <a href="./references#CD015091-fig-0015" title="">Analysis 1.8</a>) indicated no evidence of a difference between topical anesthetic and placebo. Overall, the certainty of evidence was very low because of risk of bias (−1 level) and extreme imprecision (−2 levels). </p> </section> </section> <section id="CD015091-sec-0073"> <h5 class="title">Important outcomes</h5> <section id="CD015091-sec-0074"> <h6 class="title">Treatment failure by 72 hours after treatment initiation</h6> <p>One study had no treatment failures by 72 hours; no oral analgesia was used for eye pain in either treatment group from 24 hours to two weeks (0/17 in the tetracaine compared with 0/21 in the saline group; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). The evidence was very low certainty because of risk of bias (−1 level) and imprecision (−2 levels) from the small sample size. </p> </section> <section id="CD015091-sec-0075"> <h6 class="title">Quality of life</h6> <p>None of the included trials assessed this outcome.</p> </section> </section> </section> <section id="CD015091-sec-0076"> <h4 class="title">Comparison 2: Anesthetics plus NSAID versus placebo</h4> <section id="CD015091-sec-0077"> <h5 class="title">Critical outcomes</h5> <section id="CD015091-sec-0078"> <h6 class="title">Pain control from baseline to 24 hours after treatment initiation</h6> <p>Only one post‐surgical trial compared an anesthetic plus an NSAID with placebo (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>). The single‐study effect estimate showed a large effect of the anesthetic plus NSAID on reducing pain scores at 24 hours when compared with placebo (MD ‐5.72 on a 10‐point scale, 95% CI ‐7.35 to ‐4.09; 30 participants; <a href="./references#CD015091-fig-0016" title="">Analysis 2.1</a>). The certainty of evidence was very low because of risk of bias (−1 level) and imprecision from the small sample size (−2 levels). </p> </section> <section id="CD015091-sec-0079"> <h6 class="title">Pain control from baseline to 48 hours after treatment initiation</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD015091-sec-0080"> <h6 class="title">Pain control from baseline to 72 hours after treatment initiation</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD015091-sec-0081"> <h6 class="title">Epithelial healing by 24 to 72 hours</h6> <p>From data reported in <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>, we found no evidence of an effect on epithelial healing when we compared proparacaine 0.05% plus diclofenac 0.1% with placebo (RR 0.33, 95% CI 0.04 to 2.85; 30 participants; <a href="./references#CD015091-fig-0017" title="">Analysis 2.2</a>). The certainty of evidence was very low because of risk of bias (−1 level) and imprecision (−2 levels). </p> </section> <section id="CD015091-sec-0082"> <h6 class="title">Complications reported by the longest follow‐up time</h6> <p>In <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>, the authors stated that there were no incidences of keratitis during the one‐week treatment period. Data from <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a> also indicated no evidence of a difference in ocular adverse effects between topical proparacaine 0.05% plus diclofenac 0.1% versus placebo (RD 0.00, 95% CI −0.12 to 0.12; 30 participants; <a href="./references#CD015091-fig-0018" title="">Analysis 2.3</a>). The certainty of evidence was very low because of risk of bias (−1 level) and imprecision (−2 levels). </p> </section> </section> <section id="CD015091-sec-0083"> <h5 class="title">Important outcomes</h5> <section id="CD015091-sec-0084"> <h6 class="title">Treatment failure by 72 hours</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD015091-sec-0085"> <h6 class="title">Quality of life at the longest follow‐up time</h6> <p>None of the included trials reported this outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015091-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015091-sec-0086"></div> <section id="CD015091-sec-0087"> <h3 class="title" id="CD015091-sec-0087">Summary of main results</h3> <p>In this review, we included nine randomized controlled trials (RCTs) that enrolled 314 post‐trauma participants (4 RCTs) and 242 post‐surgical participants (five RCTs) to evaluate the effectiveness and safety of topical anesthetics for relief of pain from corneal abrasion. For all outcomes of interest, the evidence that there was any important statistical or clinical difference in benefit or harm between topical anesthetic and placebo was of very low certainty because of risk of bias, outcomes that were not reported, and small sample sizes in the included trials. </p> <p>The certainty of evidence that topical anesthetics have little or no effect on reducing participant‐reported ocular pain at 24 hours for corneal abrasion after surgery or after accidental trauma when compared with placebo or a nonsteroidal anti‐inflammatory drug (NSAID) was very low. Topical anesthetics combined with an NSAID may decrease pain at 24 hours relative to placebo in post‐surgical participants (one RCT; very low certainty). Very low‐certainty evidence suggested that topical anesthetics have little or no benefit over placebo in alleviating ocular pain by 48 or 72 hours in post‐surgical participants. Compared with placebo, topical anesthetics may improve pain at 48 hours in post‐trauma participants, based on evidence of very low certainty from one trial. Topical anesthetics alone or with an NSAID may not affect the resolution of epithelial defects by 24 to 72 hours after initiation of treatment (five RCTs; very low certainty). Of the seven trials that reported assessing adverse events, the longest follow‐up ranged from six months (post‐PRK) to 48 hours (post‐pterygium surgery) with complications reported at one to two weeks. Although the evidence was of very low certainty, we found no statistical difference in adverse events at longest follow‐up between anesthetic and placebo. There were insufficient data comparing the adverse effects of topical anesthetics plus NSAID with a placebo (one RCT). </p> </section> <section id="CD015091-sec-0088"> <h3 class="title" id="CD015091-sec-0088">Overall completeness and applicability of evidence</h3> <p>Overall, there was a paucity of evidence for the comparison of efficacy or safety of topical anesthetics compared with placebo for corneal epithelial defects of traumatic or post‐surgical origin. We included randomized trials that were characterized by clinically relevant participants, routinely prescribed interventions, and patient‐important outcomes, and found the applicability of the review findings to be limited. The evidence was of very low certainty for all outcomes primarily because of small sample sizes and high risk of bias in two of the five bias domains addressed (missing outcome data and selection of study outcomes for which results had been reported). </p> <section id="CD015091-sec-0089"> <h4 class="title">Population representativeness</h4> <p>We included trials that enrolled participants with corneal abrasions of various etiologies to optimize the applicability of the review findings. However, there were systematic differences in the direction and magnitude of effect estimates between trials of post‐trauma versus post‐surgical participants. Because there were too few trials for meaningful statistical subgroup analysis, we do not know the degree to which etiology may influence specific effects. For these reasons, we did not combine outcome data from post‐trauma participants with those from post‐surgical participants. </p> <p>The findings are not applicable to pediatric populations as there was no participant younger than 17 years of age. We were interested in exploring treatment effects by gender and race, but none of the included trials provided sufficient information. There is an increasing awareness of the role that race and ethnicity may play in pain management (<a href="./references#CD015091-bbs2-0034" title="BookerSQ , BakerTA , EsiakaD , MinahanJA , EngelIJ , BanerjeeK , et al. A historical review of pain disparities research: advancing toward health equity and empowerment. Nursing Outlook 2023 Apr 4 [Epub ahead of print];71(3):101965. [DOI: 10.1016/j.outlook.2023.101965]">Booker 2023</a>; <a href="./references#CD015091-bbs2-0037" title="CampbellCM , EdwardsRR . Ethnic differences in pain and pain management. Pain Management2012;2(3):219-30.">Campbell 2012</a>; <a href="./references#CD015091-bbs2-0062" title="LetzenJE , MathurVA , JanevicMR , BurtonMD , HoodAM , MoraisCA , et al. Confronting racism in all forms of pain research: reframing study designs. Journal of Pain2022;23(6):893-912. [DOI: 10.1016/j.jpain.2022.01.010]">Letzen 2022</a>). Unfortunately, only one study reported the ethnicity of participants but did not report outcomes by ethnicity (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). The authors also discussed the influence of community culture on self‐reported pain but did provide further details (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). </p> <p>For the comparison of anesthetic versus placebo, eight of the nine trials reported the gender of participants. The predominance of male participants across the four included trials in emergency departments was consistent with previously published US surveys (<a href="./references#CD015091-bbs2-0039" title="ChannaR , ZafarSN , CannerJK , HaringRS , SchneiderEB , FriedmanDS . Epidemiology of eye-related emergency department visits. JAMA Ophthalmology2016;134(3):312-9.">Channa 2016</a>; <a href="./references#CD015091-bbs2-0068" title="McGwin G Jr, XieA , OwsleyC . Rate of eye injury in the United States. Archives of Ophthalmology2005;123(7):970-6.">McGwin 2005</a>). In the only trial that tested the combination of anesthetic and NSAID against placebo, the authors did not report the gender ratio of participants within each treatment arm (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>). On average, there was a higher proportion of women enrolled in trials of post‐ophthalmic surgeries than in those conducted in the emergency department setting (60% versus 21%, respectively). Given the growing body of literature suggesting gender differences in pain perception and reporting (<a href="./references#CD015091-bbs2-0081" title="RacineM , Tousignant-LaflammeY , KlodaLA , DionD , DupuisG , ChoinièreM . A systematic literature review of 10 years of research on sex/gender and experimental pain perception - part 1: are there really differences between women and men?Pain2012;153(3):602-18.">Racine 2012a</a>; <a href="./references#CD015091-bbs2-0082" title="RacineM , Tousignant-LaflammeY , KlodaLA , DionD , DupuisG , ChoinièreM . A systematic literature review of 10 years of research on sex/gender and pain perception - part 2: do biopsychosocial factors alter pain sensitivity differently in women and men?Pain2012;153(3):619-35.">Racine 2012b</a>), the difference in gender ratios across trials and between the two main etiologies of corneal abrasions in this review may have contributed to the heterogeneity of the observed treatment effect. </p> </section> <section id="CD015091-sec-0090"> <h4 class="title">Interventions</h4> <p>The nine included trials evaluated three of the commonly used topical anesthetics: proparacaine (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a>), tetracaine (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>), and lidocaine (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). There was only one trial in which participants received an amide anesthetic (lidocaine) in three doses over three hours prior to discharge (<a href="./references#CD015091-bbs2-0004" title="OksuzH , TamerC . Pain relief after pterygium surgery with viscous lidocaine. Ophthalmologica2006;220(5):323‐6. ">Oksuz 2006</a>). The other eight trials discharged participants with ester anesthetics: tetracaine at different concentrations with a duration of 24 to 48 hours and dilute proparacaine 0.05% for one week in three trials. The total amount dispensed and the frequency of use varied, but it was not always reported. Because of the very low certainty of evidence regarding critical outcomes, we cannot address concerns about anesthetic abuse from short‐term use of tetracaine by participants. </p> <p>Co‐interventions in several trials may confound the effects of anesthetic use and contribute to the observed heterogeneity. Depending on the trial, oral analgesia was prescribed as needed for breakthrough pain, used on a schedule to prevent breakthrough pain, or simply not permitted. Antibiotic use differed across trials by type and duration. There were also differences in the use of bandage contact lenses, occlusive patches, and supplemental topical anesthetics. </p> <p>The review findings are most applicable to ester anesthetics compared with placebo. We did not find trials comparing topical anesthetics with other common treatments, such as topical cycloplegics, and only one trial compared anesthetics with NSAIDs (<a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>). We found only one trial with dual therapy: NSAID plus anesthetic (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>). </p> </section> <section id="CD015091-sec-0091"> <h4 class="title">Outcome measurement</h4> <p>None of the included trials assessed health‐related or vision‐related quality of life or functions of daily activity. Thus, although pain is multidimensional in nature, we cannot extrapolate the very low‐certainty evidence of topical anesthetic efficacy beyond the effects on pain intensity. There is concern that sole reliance on self‐reported pain intensity can result in an overestimation of the amount of treatment needed, which is a possible contributor to the overprescribing observed in the opioid epidemic (<a href="./references#CD015091-bbs2-0079" title="Pogatzki-ZahnE , SchnabelK , KaiserU . Patient-reported outcome measures for acute and chronic pain: current knowledge and future directions. Current Opinion in Anaesthesiology2019;32(5):616-22. [DOI: 10.1097/ACO.0000000000000780]">Pogatzki‐Zahn 2019</a>; <a href="./references#CD015091-bbs2-0089" title="SharfsteinJM , OlsenY . Lessons learned from the opioid epidemic. JAMA2019;322(9):809-10. [DOI: 10.1001/jama.2019.9794]">Sharfstein 2019</a>). </p> <p>All the pain intensity measurements could be converted to 10‐point scales, which are ubiquitous and commonly used in both clinical practice and randomized trials. Similar clinically important change in pain intensity was defined in three trials, ranging from 1.5 to 2 points on a 10‐point scale (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0006" title="GarrisonL , ShipmanS , KeuchelM , PainterK . Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2019;74(4):S100. NCT04187417. Short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions. clinicaltrials.gov/show/NCT04187417 (first received 5 December 2019). ShipmanS , PainterK , KeuchelM , BogieC . Short-term topical tetracaine is highly efficacious for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Annals of Emergency Medicine2021;77(3):338‐44. ">Shipman 2021</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). These definitions overlap with other reviews of interventions for acute pain, which have defined 'moderate' effects as a change of 1 to 2 points, and 'substantial' effects as greater than a change of 2 points on a 10‐point scale (<a href="./references#CD015091-bbs2-0042" title="ChouR , WagnerJ , AhmedAY , BlazinaI , BrodtE , BuckleyDI , et al. Treatments for acute pain: a systematic review. Comparative Effectiveness Review No. 240. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290- 2015-00009-I.) AHRQ Publication No. 20(21)-EHC006. Rockville, MD: Agency for Healthcare Research and Quality; December 2020. [DOI: 10.23970/AHRQEPCCER240]">Chou 2020</a>). One trial noted that lower than 3 on a 10‐point scale is an accepted target for patients with a baseline of moderate to severe pain (<a href="./references#CD015091-bbs2-0024" title="VermaS , CorbettM , PatmoreA , HeacockG , MarshallJ . Topical anaesthesia and pain control after PRK: bupivacaine 0.75% vs amerthocaine 1%. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 919. VermaS , CorbettMC , PatmoreA , HeacockG , MarshallJ . A comparative study of the duration and efficacy of tetracaine 1% and bupivacaine 0.75% in controlling pain following photorefractive keratectomy (PRK). European Journal of Ophthalmology1997;7(4):327‐33. ">Verma 1997</a>). However, the trials included in this review were small, and only half reported participants' baseline pain, which makes it difficult to assess the sensitivity to detecting analgesic effects (<a href="./references#CD015091-bbs2-0035" title="BrinckEC , TiippanaE , HeesenM , BellRF , StraubeS , MooreRA , et al. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD012033. [DOI: 10.1002/14651858.CD012033.pub4]">Brinck 2018</a>; <a href="./references#CD015091-bbs2-0070" title="McQuayHJ , DerryS , EcclestonC , WiffenPJ , MooreRA . Evidence for analgesic effect in acute pain - 50 years on. Pain2012;153(7):1364-7.">McQuay 2012</a>; <a href="./references#CD015091-bbs2-0072" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12.">Moore 2013</a>). </p> <p>Although the pain intensity scales used in the included trials are comparable, the timing of pain intensity measurements (e.g. at 24, 48 hours; change from before and one, three, or five minutes after use of study drops), method of aggregation (e.g. score at 10 hours; overall mean scores up to 24, 48 hours; total pain burden), and type of analysis (e.g. reported value, mixed‐model for multiple time points, single factor analysis) were different in each trial. Other Cochrane Reviews of treatments for corneal abrasions found similar issues with outcome specification and reporting (<a href="./references#CD015091-bbs2-0029" title="AlgarniAM , GuyattGH , TurnerA , AlamriS . Antibiotic prophylaxis for corneal abrasion. Cochrane Database of Systematic Reviews2022, Issue 5. Art. No: CD014617. [DOI: 10.1002/14651858.CD014617.pub2]">Algarni 2022</a>; <a href="./references#CD015091-bbs2-0065" title="LimCH , TurnerA , LimBX . Patching for corneal abrasion. Cochrane Database of Systematic Reviews2016, Issue 7. Art. No: CD004764. [DOI: 10.1002/14651858.CD004764.pub3]">Lim 2016</a>; <a href="./references#CD015091-bbs2-0095" title="WakaiA , LawrensonJG , LawrensonAL , WangY , BrownMD , QuirkeM , et al. Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions. Cochrane Database of Systematic Reviews2017, Issue 5. Art. No: CD009781. [DOI: 10.1002/14651858.CD009781.pub2]">Wakai 2017</a>). </p> <p>We sought to assess the proportion of participants who did not have sufficient pain control from topical anesthetics during the periods assumed to be most painful. All the included trials had the highest pain recorded between baseline and 72 hours, but only one trial reported treatment failure over that time period (<a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a>). </p> <p>The proportion of participants who did not return for follow‐up at emergency departments was much higher than the proportion of participants not followed up in the trials conducted in the setting of ophthalmic surgery. In some of the trials conducted in the emergency department, ophthalmologists assessed participants, but most assessments were performed by emergency physicians. These provider differences in outcome measurement and assessment (interpretation) may have contributed to the clinical heterogeneity associated with the different trial settings and etiology of abrasions. The authors of <a href="./references#CD015091-bbs2-0007" title="ACTRN12605000273684. A comparison of topical anaesthesia with placebo for the managment of minor corneal trauma [Topical anaesthesia (does / does not) delay re-epithelialisation after minor corneal trauma]. anzctr.org.au/ACTRN12605000273684.aspx (first received 31 August 2005). TingJY , BarnsKJ , HolmesJL . Management of Ocular Trauma in Emergency (MOTE) trial: a pilot randomized double-blinded trial comparing topical amethocaine with saline in the outpatient management of corneal trauma. Journal of Emergencies, Trauma, and Shock2009;2(1):10-4. ">Ting 2009</a> state that only 34% (16/47) of the randomized participants returned for follow‐up at 36 to 48 hours and, therefore, the evidence remains "inconclusive" whether topical anesthetics prescribed for poor pain control after trauma could delay corneal epithelial healing. Most participants cited insignificant pain or no pain and absence of visual problems as the main reasons for noncompliance with return for follow‐up. </p> <p>The majority of trials did not report adverse events beyond one week, and only three trials reported specific adverse events. In this review we sought to synthesize the evidence in light of ongoing concerns raised by case reports and case series regarding the risks of delayed healing and ocular morbidity due to topical anesthetic abuse. The majority of cases report adverse events at time points well beyond those of the trials in this review (<a href="./references#CD015091-bbs2-0028" title="AksoyA , BaşkanAM , AslanL , AslankurtM . Topical proparacaine abuse resulting in evisceration. BMJ Case Reports2013;2013:bcr2013009539.">Aksoy 2013</a>; <a href="./references#CD015091-bbs2-0031" title="AnsariH , GaribaldiDC , JunAS . Anaesthetic abuse keratopathy as a manifestation of ocular Munchausen's syndrome. Clinical and Experimental Ophthalmology2006;34(1):81-3. [DOI: 10.1111/j.1442-9071.2006.01152.x]">Ansari 2006</a>; <a href="./references#CD015091-bbs2-0032" title="ArdjomandN , FaschingerC , Haller-SchoberEM , ScarpatettiM , FaulbornJ . A clinico-pathological case report of necrotizing ulcerating keratopathy due to topical anaesthetic abuse [Nekrotisierende ulzerierende Keratopathie nach Lokalanasthetikamissbrauch Ein klinisch-pathologischer Fallbericht]. Ophthalmologe2002;99(11):872-5. [DOI: 10.1007/s00347-002-0623-z]">Ardjomand 2002</a>; <a href="./references#CD015091-bbs2-0040" title="ChenHT , ChenKH , HsuWM . Toxic keratopathy associated with abuse of low-dose anesthetic: a case report. Cornea2004;23(5):527-9. [DOI: 10.1097/01.ico.0000114127.63670.06]">Chen 2004</a>; <a href="./references#CD015091-bbs2-0041" title="ChernKC , MeislerDM , WilhelmusKR , JonesDB , SternGA , LowderCY . Corneal anesthetic abuse and candida keratitis. Ophthalmology1996;103(1):37-40.">Chern 1996</a>; <a href="./references#CD015091-bbs2-0046" title="DornicDI , ThomasJM , LassJH . Topical diclofenac sodium in the management of anesthetic abuse keratopathy. American Journal of Ophthalmology1998;125(5):719-21. [DOI: 10.1016/s0002-9394(98)00009-9]">Dornic 1998</a>; <a href="./references#CD015091-bbs2-0047" title="EpsteinDL , PatonD . Keratitis from misuse of corneal anesthetics. New England Journal of Medicine1968;279(8):396-9.">Epstein 1968</a>; <a href="./references#CD015091-bbs2-0057" title="KatsimprisJM , SarantoulakouM , KordelouA , PetkouD , PetropoulosIK . Clinical findings in patients with topical anaesthetic abuse keratitis: a report of five cases. Klinische Monatsblatter für Augenheilkunde2007;224(4):303-8. [DOI: 10.1055/s-2007-962933]">Katsimpris 2007</a>; <a href="./references#CD015091-bbs2-0058" title="KhakshoorH , MoshirfarM , SimpsonRG , GharaeeH , VejdaniAH , ChristiansenSM , et al. Anesthetic keratopathy presenting as bilateral Mooren-like ulcers. Clinical Ophthalmology2012;6:1719-22.">Khakshoor 2012</a>; <a href="./references#CD015091-bbs2-0059" title="KimJY , ChoiYS , LeeJH . Keratitis from corneal anesthetic abuse after photorefractive keratectomy. Journal of Cataract and Refractive Surgery1997;23(3):447-9. [DOI: 10.1016/s0886-3350(97)80192-7]">Kim 1997</a>; <a href="./references#CD015091-bbs2-0060" title="LeeJK , StarkWJ . Anesthetic keratopathy after photorefractive keratectomy. Journal of Cataract and Refractive Surgery2008;34(10):1803-5.">Lee 2008</a>; <a href="./references#CD015091-bbs2-0078" title="PharmakakisNM , KatsimprisJM , MelachrinouMP , KoliopoulosJX . Corneal complications following abuse of topical anesthetics. European Journal of Ophthalmology2002;12(5):373-8. [DOI: 10.1177/112067210201200505]">Pharmakakis 2002</a>; <a href="./references#CD015091-bbs2-0084" title="RosenwasserGO , HollandS , PflugfelderSC , LugoM , HeidemannDG , CulbertsonWW , et al. Topical anesthetic abuse. Ophthalmology1990;97(8):967-72.">Rosenwasser 1990</a>; <a href="./references#CD015091-bbs2-0093" title="VargaJH , RubinfeldRS , WolfTC , StutzmanRD , PeeleKA , CliffordWS , et al. Topical anesthetic abuse ring keratitis: report of four cases. Cornea1997;16(4):424-9.">Varga 1997</a>; <a href="./references#CD015091-bbs2-0097" title="WebberSK , SuttonGL , LawlessMA , RogersCM . Ring keratitis from topical anaesthetic misuse. Australian and New Zealand Journal of Ophthalmology1999;27(6):440-2. [DOI: 10.1046/j.1440-1606.1999.00246.x]">Webber 1999</a>; <a href="./references#CD015091-bbs2-0099" title="WillisWE , LaibsonPR . Corneal complications of topical anesthetic abuse. Canadian Journal of Ophthalmology1970;5(3):239-43.">Willis 1970</a>; <a href="./references#CD015091-bbs2-0100" title="WuH , HuY , ShiXR , XuF , JiangCY , HuangR , et al. Keratopathy due to ophthalmic drug abuse with corneal melting and perforation presenting as Mooren-like ulcer: A case report. Experimental and Therapeutic Medicine2016;12(1):343-6. [DOI: 10.3892/etm.2016.3296]">Wu 2016</a>; <a href="./references#CD015091-bbs2-0101" title="YagciA , BozkurtB , EgrilmezS , PalamarM , OzturkBT , PekelH . Topical anesthetic abuse keratopathy: a commonly overlooked health care problem. Cornea2011;30(5):571-5. [DOI: 10.1097/ico.0b013e3182000af9]">Yagci 2011</a>). For example, in Turkey, where topical anesthetics were available over the counter until 2012, one study found that median drug use was 28 days (range: 10 to 112 days; seven patients) before admission to clinic for amniotic membrane transplantation (<a href="./references#CD015091-bbs2-0036" title="BurcuA , DoganE , Yalniz-AkkayaZ , OrnekF . Early amniotic membrane transplantation for toxic keratopathy secondary to topical proparacaine abuse: a report of seven cases. Cutaneous and Ocular Toxicology2013;32(3):241-7. [DOI: 10.3109/15569527.2012.759959]">Burcu 2013</a>). Another case series reported that epithelial healing took a median of 17 days (range: 6 to 50 days; 19 patients) in patients diagnosed with topical anesthetic abuse keratopathy (<a href="./references#CD015091-bbs2-0101" title="YagciA , BozkurtB , EgrilmezS , PalamarM , OzturkBT , PekelH . Topical anesthetic abuse keratopathy: a commonly overlooked health care problem. Cornea2011;30(5):571-5. [DOI: 10.1097/ico.0b013e3182000af9]">Yagci 2011</a>). The findings of the current review cannot address whether these cases of anesthetic abuse are outliers or the norm since the majority of included trials did not clinically assess safety outcomes beyond one to two weeks. </p> <p>The time from the corneal abrasion to participant randomization was longer in the acute trauma setting than the post‐surgical setting by 24 to 36 hours, depending on the trial. Post‐trauma trials varied in whether investigators included patients with rust rings, which has implications for potential risk of bias and for the applicability of findings. In the post‐surgical trials, the abrasion depth and area were more uniformly controlled and created in a sterile field. The baseline risk for healing time and adverse events such as microbial keratitis may differ systematically by setting. </p> </section> </section> <section id="CD015091-sec-0092"> <h3 class="title" id="CD015091-sec-0092">Certainty of the evidence</h3> <p>We downgraded the certainty of evidence for most review outcomes because of risk of bias from missing outcome data and selection of the outcome results that had been reported, and because of imprecision of effect estimates based on small sample sizes. Aside from the clinical heterogeneity in the trial design and conduct (trial setting, dosage of intervention and co‐intervention, outcome measurement, method of aggregation, types of analysis, time of outcome assessment, and duration of follow‐up) and in patient characteristics (etiologies of abrasion, presence or absence of rust rings, which might have influenced dropout from post‐trauma trials), other reasons for the observed statistical heterogeneity included differences in the directions of effects between trials. The small number of trials limited our ability to explore these factors in depth. Of the nine included trials, we found trial registration records for only four trials; only one had been registered before participant enrollment began. </p> </section> <section id="CD015091-sec-0093"> <h3 class="title" id="CD015091-sec-0093">Potential biases in the review process</h3> <p>We aimed to minimize potential biases in the review process by applying standard Cochrane methodology. We contacted study authors during the screening of full‐text reports to minimize the exclusion of eligible trials. We clarified with investigators regarding conflicting information found in reports from the same study, trials halted prior to enrollment, and clarifications of issues regarding randomization. We did not exclude the one study for which we did not receive a response (<a href="./references#CD015091-bbs2-0026" title="AseffA , ValdezJ , VargasJ , VidaurriJ . Wound healing and patient discomfort after excimer photorefractive keratectomy with topical diclofenac vs topic tetracaine. Investigative Ophthalmology and Visual Science1997;38:ARVO Abstract 2465. ">Aseff 1997</a>). We also received raw data for two outcome time points from one of the authors (<a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>). We included trials regardless of language of publication and translated study reports to the extent necessary (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>). One limitation of this review is that estimates of rates of serious adverse events may be under‐reported either because of rarity, the method of elicitation of reports of complications, or under‐reporting by the study investigators. This limitation prevented us from assessing the safety of the intervention to permit readers to balance efficacy and safety. </p> </section> <section id="CD015091-sec-0094"> <h3 class="title" id="CD015091-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>Three reviews that included multiple interventions for post‐PRK pain management have discussed the use of topical anesthetics for pain management (<a href="./references#CD015091-bbs2-0048" title="GarciaR , deAndradeDC , TeixeiraMJ , NozakiSS , BecharaSJ . Mechanisms of corneal pain and implications for postoperative pain after laser correction of refractive errors. Clinical Journal of Pain2016;32(1):450-8.">Garcia 2016</a>; <a href="./references#CD015091-bbs2-0051" title="GolanO , RandlemanJB . Pain management after photorefractive keratectomy. Current Opinion in Ophthalmology2018;29:306-12.">Golan 2018</a>; <a href="./references#CD015091-bbs2-0090" title="SteiglemanWA , Rose-NussbaumerJ , Al-MohtasebZ , SanthiagoMR , LinCC , PantanelliSM , et al. Management of pain after photorefractive keratectomy: a report by the American Academy of Ophthalmology. Ophthalmology2023;130(1):87-98. [DOI: 10.1016/j.ophtha.2022.07.028]">Steigleman 2023</a>). The <a href="./references#CD015091-bbs2-0051" title="GolanO , RandlemanJB . Pain management after photorefractive keratectomy. Current Opinion in Ophthalmology2018;29:306-12.">Golan 2018</a> review recommended against the long‐term use of topical anesthetics, while <a href="./references#CD015091-bbs2-0048" title="GarciaR , deAndradeDC , TeixeiraMJ , NozakiSS , BecharaSJ . Mechanisms of corneal pain and implications for postoperative pain after laser correction of refractive errors. Clinical Journal of Pain2016;32(1):450-8.">Garcia 2016</a> stated that based on three studies (including <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a> in our review), topical anesthetics did not delay epithelial healing. The conclusions of the authors of the third review were more measured and highlighted the need for careful monitoring (<a href="./references#CD015091-bbs2-0090" title="SteiglemanWA , Rose-NussbaumerJ , Al-MohtasebZ , SanthiagoMR , LinCC , PantanelliSM , et al. Management of pain after photorefractive keratectomy: a report by the American Academy of Ophthalmology. Ophthalmology2023;130(1):87-98. [DOI: 10.1016/j.ophtha.2022.07.028]">Steigleman 2023</a>). Different inclusion criteria may account for these varying conclusions as both <a href="./references#CD015091-bbs2-0051" title="GolanO , RandlemanJB . Pain management after photorefractive keratectomy. Current Opinion in Ophthalmology2018;29:306-12.">Golan 2018</a> and <a href="./references#CD015091-bbs2-0090" title="SteiglemanWA , Rose-NussbaumerJ , Al-MohtasebZ , SanthiagoMR , LinCC , PantanelliSM , et al. Management of pain after photorefractive keratectomy: a report by the American Academy of Ophthalmology. Ophthalmology2023;130(1):87-98. [DOI: 10.1016/j.ophtha.2022.07.028]">Steigleman 2023</a> included the same trials, while the <a href="./references#CD015091-bbs2-0005" title="JagerR , JainS , SanisloS , AckermanJ , Miller, ShahinianL . The effect of topical dilute proparacaine on relief of postoperative PRK pain. Investigative Ophthalmology and Visual Science1996;37:ARVO Abstract 2650. ShahinianL , JainS , JagerRD , LinDT , SanisloSS , MillerJF . Dilute topical proparacaine for pain relief after photorefractive keratectomy. Ophthalmology1997;104(8):1327‐32. ShahinianL , JainS , JagerRD , SanisloSR , LinDT , MillerJF . Dilute topical proparacaine for pain control following photorefractive keratectomy (PRK). In: American Academy of Ophthalmology Annual Meeting; 1996 Oct 27-31; Chicago (IL). 1996:116. ">Shahinian 1997</a> trial was omitted from <a href="./references#CD015091-bbs2-0048" title="GarciaR , deAndradeDC , TeixeiraMJ , NozakiSS , BecharaSJ . Mechanisms of corneal pain and implications for postoperative pain after laser correction of refractive errors. Clinical Journal of Pain2016;32(1):450-8.">Garcia 2016</a>. We included two non‐English language trials that were excluded from the above reviews based on the publication language (<a href="./references#CD015091-bbs2-0002" title="LimHT , KimYK , TchahHW . Efficacy of topical NSAIDs and anesthetic drug in reducing post-PRK pain: comparative study [PRK 후 통증치료에 대한 점안 비스테로이드성 항염증약제들과 점안 마취제의 효과 비교]. Journal of the Korean Ophthalmological Society1999;40(1):61‐9. ">Lim 1999</a>; <a href="./references#CD015091-bbs2-0003" title="MontardM , ChopinC , DelboscB , MuhieddineM . Tetracaine versus diclofenac in the treatment of pain following refractive photokeratectomy [Tétracaïne versus diclofénac dans le traitement de la douleur après photokératectomie réfractive]. Journal Francais d’Ophtalmologie1999;22(1):14‐20. ">Montard 1999</a>). Although their inclusion did not provide further certainty regarding the safety or efficacy of topical anesthetics, it highlights the potential for bias introduced by restricting studies included in reviews by language of publication. </p> <p>A systematic review of RCTs evaluating the safety and efficacy of topical proparacaine and tetracaine for corneal abrasions (<a href="./references#CD015091-bbs2-0091" title="SwaminathanA , OtternessK , MilneK , RezaieS . The safety of topical anesthetics in the treatment of corneal abrasions: a review. Journal of Emergency Medicine2015;49(5):810-5.">Swaminathan 2015</a>) included several studies included in our review (<a href="./references#CD015091-bbs2-0001" title="BallIM , SeabrookJ , DesaiN , AllenL , AndersonS . Dilute proparacaine for the management of acute corneal injuries in the emergency department. Canadian Journal of Emergency Medicine2010;12(5):389‐96. NCT00620997. Proparacaine vs placebo for corneal injuries. clinicaltrials.gov/show/NCT00620997 (first received 22 February 2008). ">Ball 2010</a>; <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>; <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a>). These authors originally intended to review corneal abrasions seen in the emergency department. However, the selection was expanded to also include patients who underwent PRK because of a paucity of studies identified in their original search. Their conclusion was that topical anesthetics were safe and effective for corneal abrasions either from trauma or after PRK. It is important to note that these authors did not perform a statistical meta‐analysis, nor did they quantify the methodological rigor (e.g. risk of bias) of studies or the level of certainty in the data. </p> <p>A more recent systematic review of RCTs and observational studies included several types of topical interventions for pain control (NSAIDs, bandage contact lenses, patching, topical anesthetics) compared with placebo or no treatment for traumatic corneal abrasions (<a href="./references#CD015091-bbs2-0102" title="YuCW , KirubarajanA , YauM , ArmstrongD , JohnsonDE . Topical pain control for corneal abrasions: a systematic review and meta-analysis. Academic Emergency Medicine2021;28(8):890-908. [DOI: 10.1111/acem.14222]">Yu 2021</a>). They explicitly excluded post‐surgical studies. For the comparison of topical anesthetics with placebo, <a href="./references#CD015091-bbs2-0102" title="YuCW , KirubarajanA , YauM , ArmstrongD , JohnsonDE . Topical pain control for corneal abrasions: a systematic review and meta-analysis. Academic Emergency Medicine2021;28(8):890-908. [DOI: 10.1111/acem.14222]">Yu 2021</a> included the same four randomized controlled trials (RCTs) and one observational study that we excluded (<a href="./references#CD015091-bbs2-0096" title="WaldmanN , WinrowB , DensieI , GrayA , McMasterS , GiddingsG , et al. An observational study to determine whether routinely sending patients home with a 24-hour supply of topical tetracaine from the emergency department for simple corneal abrasion pain is potentially safe. Annals of Emergency Medicine2018;71(6):767-78.">Waldman 2018</a>). Based on this trial, <a href="./references#CD015091-bbs2-0102" title="YuCW , KirubarajanA , YauM , ArmstrongD , JohnsonDE . Topical pain control for corneal abrasions: a systematic review and meta-analysis. Academic Emergency Medicine2021;28(8):890-908. [DOI: 10.1111/acem.14222]">Yu 2021</a> noted that there may be differences in adverse outcomes based on corneal abrasion complexity (e.g. size of abrasion). Our review did not explore differences in outcomes based on corneal abrasion size. However, it is worth noting that the post‐surgical trials did report grouping by the abrasion size. Our review is in agreement with <a href="./references#CD015091-bbs2-0102" title="YuCW , KirubarajanA , YauM , ArmstrongD , JohnsonDE . Topical pain control for corneal abrasions: a systematic review and meta-analysis. Academic Emergency Medicine2021;28(8):890-908. [DOI: 10.1111/acem.14222]">Yu 2021</a> on the absence of definitive evidence regarding safety outcomes, although our count of participants and complications differs. The reason for this difference may be from the review author's classification of complications and the specified time point. The authors of <a href="./references#CD015091-bbs2-0102" title="YuCW , KirubarajanA , YauM , ArmstrongD , JohnsonDE . Topical pain control for corneal abrasions: a systematic review and meta-analysis. Academic Emergency Medicine2021;28(8):890-908. [DOI: 10.1111/acem.14222]">Yu 2021</a> recommend, "If topical anesthesia is given to the patient, we advocate for formulations such as dilute proparacaine as opposed to tetracaine, the latter being available in clinics largely to facilitate ocular examination." In our review, there was insufficient evidence, even with the inclusion of post‐surgical trials, to support or refute such a recommendation. </p> <p>We focused solely on topical anesthetics. A number of treatment modalities for pain following PRK were highlighted in <a href="./references#CD015091-bbs2-0090" title="SteiglemanWA , Rose-NussbaumerJ , Al-MohtasebZ , SanthiagoMR , LinCC , PantanelliSM , et al. Management of pain after photorefractive keratectomy: a report by the American Academy of Ophthalmology. Ophthalmology2023;130(1):87-98. [DOI: 10.1016/j.ophtha.2022.07.028]">Steigleman 2023</a> but were not included in <a href="./references#CD015091-bbs2-0102" title="YuCW , KirubarajanA , YauM , ArmstrongD , JohnsonDE . Topical pain control for corneal abrasions: a systematic review and meta-analysis. Academic Emergency Medicine2021;28(8):890-908. [DOI: 10.1111/acem.14222]">Yu 2021</a>, possibly reflecting the inherent differences between diagnosis and management of post‐surgical epithelial defects and traumatic corneal abrasions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015091-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD015091-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias: Change in participant‐reported ocular pain from baseline to 48 hours" data-id="CD015091-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias: Change in participant‐reported ocular pain from baseline to 48 hours</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias: Proportion of participants with complications at longest time point" data-id="CD015091-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias: Proportion of participants with complications at longest time point</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.1 Change in participant‐reported ocular pain from baseline to 24 hours" data-id="CD015091-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.1 Change in participant‐reported ocular pain from baseline to 24 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.2 Change in participant‐reported ocular pain from baseline to 48 hours" data-id="CD015091-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.2 Change in participant‐reported ocular pain from baseline to 48 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.5 Proportion of eyes without complete resolution of epithelial defects by 24 to 72 hours" data-id="CD015091-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.5 Proportion of eyes without complete resolution of epithelial defects by 24 to 72 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.7 Proportion of individuals/eyes with complications at furthest time point" data-id="CD015091-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison 1: topical anesthetic vs placebo, outcome: 1.7 Proportion of individuals/eyes with complications at furthest time point </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 1: Change in participant‐reported ocular pain from baseline to 24 hours" data-id="CD015091-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 1: Change in participant‐reported ocular pain from baseline to 24 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 2: Change in participant‐reported ocular pain from baseline to 48 hours" data-id="CD015091-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 2: Change in participant‐reported ocular pain from baseline to 48 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 3: Change in participant‐reported ocular pain from baseline to 72 hours" data-id="CD015091-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 3: Change in participant‐reported ocular pain from baseline to 72 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 4: Proportion of post‐trauma participants without complete resolution of epithelial defects by 24 to 72 hours ‐ subgroup by tetracaine concentration" data-id="CD015091-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 4: Proportion of post‐trauma participants without complete resolution of epithelial defects by 24 to 72 hours ‐ subgroup by tetracaine concentration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 5: Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours" data-id="CD015091-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 5: Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 6: Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours ‐ subgroup by duration of use (RD)" data-id="CD015091-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 6: Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours ‐ subgroup by duration of use (RD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 7: Proportion of participants with complications at furthest time point" data-id="CD015091-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 7: Proportion of participants with complications at furthest time point </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anesthetic vs placebo or NSAID, Outcome 8: Proportion of participants with complications at furthest time point (RD) ‐ subgroup by abrasion type" data-id="CD015091-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Anesthetic vs placebo or NSAID, Outcome 8: Proportion of participants with complications at furthest time point (RD) ‐ subgroup by abrasion type </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anesthetic + NSAID vs placebo, Outcome 1: Change in participant‐reported ocular pain from baseline to 24 hours" data-id="CD015091-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Anesthetic + NSAID vs placebo, Outcome 1: Change in participant‐reported ocular pain from baseline to 24 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anesthetic + NSAID vs placebo, Outcome 2: Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours" data-id="CD015091-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Anesthetic + NSAID vs placebo, Outcome 2: Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015091-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/urn:x-wiley:14651858:media:CD015091:CD015091-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anesthetic + NSAID vs placebo, Outcome 3: Proportion of participants with complications at furthest time point (RD)" data-id="CD015091-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_t/tCD015091-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Anesthetic + NSAID vs placebo, Outcome 3: Proportion of participants with complications at furthest time point (RD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/media/CDSR/CD015091/image_n/nCD015091-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015091-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical ophthalmic anesthetic compared with placebo or NSAID</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Topical ophthalmic anesthetic compared with placebo or NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patients or population:</b> corneal abrasion (post‐trauma or post‐surgical) </p> <p><b>Settings:</b> emergency department or ophthalmology surgery </p> <p><b>Intervention:</b> anesthetic (tetracaine, proparacaine, lidocaine) </p> <p><b>Comparison:</b> placebo or NSAID (diclofenac, artificial tears, saline) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Relative effect <b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with anesthetic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 24 hours</b><br/>Assessed with: VAS pain intensity </p> <p>0 to 10</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Lower is better.</p> <p>The original VAS was from 0 to 100 in <a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a>, which compared tetracaine 1% with placebo in post‐trauma participants. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 3.63 (SD 1.00)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 1.28 lower (0.80 to 1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119<br/>(3 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> (see comment) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 0.11 (SD 0.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.04 lower (0.10 lower to 0.02 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>NSAID, post‐surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 2.09 (SD 1.77)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.82 higher (0.01 to 1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 48 hours</b><br/>Assessed with: VAS pain intensity </p> <p>0 to 10</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Lower is better.</p> <p><a href="./references#CD015091-bbs2-0009" title='ACTRN12611000448943. A prospective, randomized, double-blind trial to evaluate the role of topical anaesthetics in controlling pain after corneal abrasion in the emergency department. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000448943 (first received 5 March 2011). PruetCM , FeldmanRM , KimG . Re: "Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial". Academic Emergency Medicine2014;21(9):1062. TijunelisM , TozerK . Good study design, but flawed conclusion in emergency department tetracaine use. Academic Emergency Medicine2014;21(11):1302-3. WaldmanN , DensieIK , HerbisonP . Topical tetracaine used for 24 hours is safe and rated highly effective by patients for the treatment of pain caused by corneal abrasions: a double-blind, randomized clinical trial. Academic Emergency Medicine2014;21(4):374‐82. WaldmanN , DensieIK . Good study design, but flawed conclusion in emergency department tetracaine use. In reply. Academic Emergency Medicine2014;21(11):1304-5. '>Waldman 2014</a> was excluded from the analysis due to missing data. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 0.81 (SD 1.46)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.41 higher (0.45 lower to 1.27 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 7.23 (SD 1.95)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 5.68 lower (4.98 lower to 6.38 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 72 hours</b><br/>Assessed with: VAS pain intensity </p> <p>0 to 10</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 0.2 (SD 0.83)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 0.49 higher (0.06 lower to 1.04 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower is better.</p> <p>Only <a href="./references#CD015091-bbs2-0008" title="VermaS , CorbettMC , MarshallJ , HamiltonPAM . Pain control after PRK: do topical anesthetics have a role?American Academy of Ophthalmology1995;1:102. VermaS , CorbettMC , MarshallJ . A prospective, randomized, double-masked trial to evaluate the role of topical anesthetics in controlling pain after photorefractive keratectomy. Ophthalmology1995;102(12):1918‐24. VermaS , CorbettMC , MarshallJ . Topical anaesthesia and pain control after PRK: visual performance and cellular correlates. Investigative Ophthalmology and Visual Science1995;36:ARVO Abstract 4892. ">Verma 1995</a> reported pain outcomes beyond 48 hours (at 64 hours). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>b,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR &lt; 1 is better.</p> <p>Another post‐surgery trial (44 participants) reported no events in either arm.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>152 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> <p>(118 to 367)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.37 (0.78 to 2.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221</p> <p>(3 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> <p>(2 to 510)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14 (0.01 to 2.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportion of participants with complications at longest time point</b> </p> <p>Up to 2 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐trauma</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR &lt; 1 is better.</p> <p>Two post‐surgical trials (75 participants) and one post‐trauma trial (33 participants) reported no events in either arm. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> <p>(15 to 355)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.13 (0.23 to 5.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242</p> <p>(3 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>Placebo, post‐surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> <p>(1 to 356)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.00 (0.38 to 128.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**The corresponding risk was the absolute risk (number of events divided by number of participants in the intervention group). The 95% CI was calculated using a binomial distribution. </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NSAID:</b> nonsteroidal anti‐inflammatory drug; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analog scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for serious risk of bias (−2 levels).<br/><sup>b</sup>Downgraded for imprecision (−1 level).<br/><sup>c</sup>Downgraded for indirectness (−1 level).<br/><sup>d</sup>Downgraded for risk of bias (−1 level).<br/><sup>e</sup>Downgraded for inconsistency (−1 level).<br/><sup>f</sup>Downgraded for extreme imprecision (−2 levels). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical ophthalmic anesthetic compared with placebo or NSAID</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015091-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical ophthalmic anesthetic plus NSAID compared with placebo</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Topical ophthalmic anesthetic plus NSAID compared with placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patients or population:</b> corneal abrasion (post‐surgical) </p> <p><b>Settings:</b> ophthalmology surgery </p> <p><b>Intervention:</b> anesthetic with NSAID (proparacaine plus diclofenac) </p> <p><b>Comparison:</b> placebo (artificial tears) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p>Relative effect <b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants (RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with anesthetic plus NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 24 hours</b><br/>VAS (scale 0 to 10) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the comparison group was 8.08 (SD 2.28)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in the intervention group was 5.72 lower (4.09 lower to 7.35 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 48 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in mean participant‐reported ocular pain from baseline to 72 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/>(8 to 570) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/>(0.04 to 2.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &lt; 1 is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with complications at longest time point</b> </p> <p>Up to 1 week</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No adverse events reported in either arm.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &lt; 1 is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NSAID:</b> nonsteroidal anti‐inflammatory; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analog scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (−1 level). <br/><sup>b</sup>Downgraded for extreme imprecision (−2 levels). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical ophthalmic anesthetic plus NSAID compared with placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015091-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Etiology</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention(s)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison(s)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Co‐intervention(s)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. participants randomized/analyzed, intervention arm</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. participants randomized/analyzed, control arm</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention duration</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Note</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ball 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proparacaine 0.05%</p> <p>2 to 4 drops, as needed, for 7 days, max dispensed 40 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops</p> <p>(color and smell‐ matched)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: gatifloxacin, 1 drop every 2 hours, for 7 days<br/>OA: 325 mg acetaminophen with 30 mg of codeine, 1 to 2 tablets every 4 hours if needed, for 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lim 1999</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) Proparacaine 0.05%<br/>2) Diclofenac 0.1% + proparacaine 0.05% </p> <p>1 drop every 4 hours for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> <p>(Tears Natural)</p> <p>1 drop every 4 hours for 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: ofloxacine, every 6 hours, for 1 week<br/>OA: mefenamic acid, as needed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1) 15/15<br/>2) 15/15 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 of 7 treatment arms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Montard 1999</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 1% every 30 minutes for 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diclofenac 0.1% every 4 hours for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: ofloxacine, every 6 hours, for 1 week<br/>OA: mefenamic acid, as needed<br/>Other: BCLs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Oksuz 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pterygium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lidocaine 2%<sup>c</sup> </p> <p>1 mL every hour for 3 hours, starting 1 hour postop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears<sup>c</sup> </p> <p>(Thilo‐Tears Jelly)</p> <p>1 mL every hour for 3 hours, starting 1 hour postop</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: NR<br/>OA: none<br/>Other: patched </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shahinian 1997</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada and US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proparacaine 0.05%</p> <p>1 drop 4 times a day for 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> <p>(Hypotears)</p> <p>1 drop 4 times a day for 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: 0.3% tobramycin and 0.1% dexamethasone, 4 times a day, over 1 week<br/>OA: acetaminophen and hydrocodone bitartrate, as needed, over 1 week<br/>Topical: topical diclofenac 0.1%, 4 times a day, for the first 48 hours<br/>Other: BCLs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 eyes/25 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 eyes/23 eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Shipman 2021</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 0.5%</p> <p>1 drop every 30 minutes as needed for 24 hours, max dispensed 2 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artificial tears</p> <p>(Systane)</p> <p>1 drop every 30 minutes as needed for 24 hours, max dispensed 2 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: polymyxin B sulfate/trimethoprim sulfate, 2 drops every 4 hours, max 24 hours<br/>OA: hydrocodone 7.5 mg/acetaminophen 325 mg, 1 to 2 tablets as needed every 6 hours, max 12 tablets </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ting 2009</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 0.4%</p> <p>1 drop every hour as needed for 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops 0.9%</p> <p>1 drop every hour as needed for 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: topical antibiotics (unspecified)<sup>a</sup><br/>OA: oral analgesics (unspecified) as needed for eye pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 to 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Verma 1995</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 1%<sup>d</sup> </p> <p>1 drop every 30 minutes during waking hours for 24 hours, max dispensed 40 drops</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops<sup>d</sup> </p> <p>(physiologic saline)</p> <p>1 drop every 30 minutes during waking hours for 24 hours, max dispensed 40 drops</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: chloramphenicol 0.5%, topical, 1 drop every 6 hours, over 1 week<br/>OA: co‐proxamol, 2 tablets every 8 hours, over 2 days<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Waldman 2014</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracaine 1% as needed, up to every 30 minutes for 24 hours, max dispensed 1.5 mL (50 drops) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saline drops 0.9% as needed, up to every 30 minutes for 24 hours, max dispensed 1.5 mL (50 drops) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AB: preservative‐free chloramphenicol antibiotics 1%, topical ointment<br/>OA: paracetamol 500 mg, 2 tablets at 08:00, 12:00, 16:00, 20:00, oral, over 24 hours<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>AB:</b> topical antibiotics; <b>BCLs:</b> bandage contact lenses; <b>NR:</b> not reported; <b>OA:</b> oral anesthetic; <b>PRK:</b> photorefractive keratectomy<br/><sup>a</sup>Not all participants received antibiotics (8/22 participants in the tetracaine group and 8/18 in the saline group received antibiotics).<br/><sup>b</sup>The study prescribed oral anesthetic to prevent breakthrough pain.<br/><sup>c</sup>Prescribed at 1, 2, and 3 hours postop, inpatient setting. Not taken on an as‐needed basis.<br/><sup>d</sup>Prescribed at a specific schedule. Not taken on an as‐needed basis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/full#CD015091-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015091-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anesthetic vs placebo or NSAID</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in participant‐reported ocular pain from baseline to 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Anesthetic vs placebo, VAS (0 to 10), post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐1.76, ‐0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Anesthetic vs placebo, VAS (0 to 10), post‐trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.10, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Anesthetic vs NSAID, VAS (0 to 10), post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.01, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change in participant‐reported ocular pain from baseline to 48 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Anesthetic vs placebo, VAS (0 to 10), post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.45, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Anesthetic vs placebo, VAS (0 to 10), post‐trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.68 [‐6.38, ‐4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in participant‐reported ocular pain from baseline to 72 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Proportion of post‐trauma participants without complete resolution of epithelial defects by 24 to 72 hours ‐ subgroup by tetracaine concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.78, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Tetracaine 0.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.29, 22.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Tetracaine 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.65, 4.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Tetracaine 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.53, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 24 to 48 hours, post‐trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.78, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 48 hours or longer, post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours ‐ subgroup by duration of use (RD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 24 to 48 hours, post‐trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.04, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 24 to 48 hours, post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.08, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 48 hours or longer, post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.42, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Proportion of participants with complications at furthest time point <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At 1 week, post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.38, 128.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 At 1 to 2 weeks, post‐trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.23, 5.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Proportion of participants with complications at furthest time point (RD) ‐ subgroup by abrasion type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.03, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Post‐surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.06, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Post‐trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.06, 0.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anesthetic vs placebo or NSAID</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015091-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anesthetic + NSAID vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Change in participant‐reported ocular pain from baseline to 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Proportion of participants with complications at furthest time point (RD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anesthetic + NSAID vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#CD015091-tbl-0005">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Change in participant‐reported ocular pain from baseline to 48 hours</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.2.1 Anesthetic vs placebo, VAS (0 to 10), post‐surgery</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Verma 1995</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Patients were allocated drops based on a random‐number generator, and prenumbered containers were dispensed by the operating surgeon." Baseline characteristics of study participants were partially reported by refractive error groups, not by treatment group. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eye drops were prenumbered and dispensed by the operating surgeon; the reference code was opened 3 months postoperatively. A p‐value was reported along with the pain scores but the authors did not report how the p‐value was derived. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for all 44 participants randomized were analyzed and reported.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All patients were asked to complete Visual Analogue Pain Charts which consisted of a series of horizontal lines 10 em in length with "no pain" written at one end and "worst pain imaginable" at the other. Both participants and the surgeon were likely masked to the eye drops patients received. All pain score data at pre‐specified time points were reported as mean and standard errors in a figure. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No study protocol for evaluation but pain scores were reported as a continuous measure. Data for all timepoints pre‐specified were reported in figures. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial was assessed to be at some concern for bias due to deviations from intended interventions. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.2.2 Anesthetic vs placebo, VAS (0 to 10), post‐trauma</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Shipman 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation list was generated by a computer random‐number generator and randomization was performed with numbered, sealed, opaque envelopes issued in sequential order to the physician enrolling the patient in the study. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The envelopes were opaque to ensure enrolling physicians remained blinded despite the different packaging of the placebo and the tetracaine. The placebo and tetracaine were labeled for the patient as the “study drops” to maintain blinding. Intention‐to‐treat analysis used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up for 3/59 (5.1%) tetracaine and 4/59 (6.8%) placebo. "Data for all participants who underwent random assignment were analyzed according to group assignment" </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were asked to record pain score measurements on a standard NRS (from 0 to 10 cm), which was appropriate. Both participants and physicians were masked to treatment assignment. Data were analyzed without showing patient ID, i.e. masked to the treatment assignment. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>In the methods section, primary outcome data were reported to be analyzed by the Wilcoxon signed‐rank test, whereas in the results section, pain scores were compared and reported as mean difference and its associated 95% CI. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial was assessed to be at a high risk of bias due to bias in selection of the reported result. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Change in participant‐reported ocular pain from baseline to 48 hours</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Proportion of participants with complications at furthest time point</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.1 At 1 week, post‐surgery</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Verma 1995</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Patients were allocated drops based on a random‐number generator, and prenumbered containers were dispensed by the operating surgeon." Baseline characteristics of study participants were partially reported by refractive error groups, not by treatment group. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Medications were contained in prenumbered containers and delivered by the operating surgeon who appeared to be masked too. ITT analysis of all participants. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The number of participants who lost to follow‐up was not reported by time point. It was unclear how many participants returned after post‐op week one. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The current outcome was self‐reported but was further verified by an objective surface exam (topography) and visual acuity examination for all participants who returned at week one follow‐up.<br/>The randomization code was not broken before post‐op month three. Outcome assessors were likely masked. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported at week one, month one, and month six as pre‐defined, except for post‐op month three.<br/>There are multiple assessments, but the reporting appears to include the details of each case. <br/>The result is dichotomous and the details of the specific assessment results are reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at a low risk of bias in all domains.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.7.2 At 1 to 2 weeks, post‐trauma</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ting 2009</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of randomization was not described beyond stating it is a randomized trial. The research pharmacists not involved in the design or conduct of the trial, prepared identical, clear minim packs that were "sent to the ED in no particular order." <br/>There are minimal differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The containers were in clear, identical containers. The investigators did not indicate that toxicity (such as burning) prevented this. The study used a modified ITT analysis, excluding participants who had missing data at the 2 weeks assessment. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for 83% of participants randomized: 17/22 in the amethocaine group and 21/25 in the saline group (post‐hoc p &gt; 0.05). <br/>There is no evidence provided (such as a sensitivity analysis) to determine if there was biased data. <br/>The missing data could depend on its true value. During the week 2 phone interview followup, the reasons reported by participants for not attending the 36‐48 hr visit was pain relief and no visual problems. There is insufficient information to determine whether this was likely to be the case or if the missing data was due to complications. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The slitlamp assessment by an emergency department physician at 36 to 48 hours is appropriate. The phone interview assessment of complications at 2 weeks is not detailed in the article, though it may not be appropriate for determining many types of adverse events. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registration does not specify assessment of complications. No trial protocol or statistical analysis plan was included. There is no information provided about how complications were assessed at the 36‐48 hr, 2 weeks, or throughout the study. <br/>There is insufficient detail to determine whether the result may have been selected on the basis of analysis. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to missing outcome data; some concerns in the measurement of the outcome and in selection of the reported result. </p> </td> </tr> <tr class="study-data"> <td> <p>Shipman 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation list was generated by a computer random‐number generator and randomization was performed with numbered, sealed, opaque envelopes issued in sequential order to the physician enrolling the patient in the study. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The placebo and tetracaine were labeled for the patient as the “study drops” to maintain blinding. However, although we attempted to blind patients from their allocation group, the burning nature of the tetracaine may have unblinded the patients.<br/>Additionally, patients may have been unblinded as a result of the placebo having been packaged in 4 ampules versus the tetracaine in a single bottle. Data for all randomized participants were analyzed according to group assignment in an intention‐to‐treat fashion. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up for 3/59 (5.1%) in the tetracaine groups and 4/59 (6.8%) in the placebo group. In the tetracaine group, of the 48 patients who did not complete all follow‐ups, 16 responded to a text message, reporting no study‐associated complications. In the placebo group, 4 patients did not attend the emergency department follow‐up visit and 45 did not return for their 1‐week follow‐up with the study ophthalmologist. Of these 49 patients who did not complete all follow‐ups, 6 responded to a text message, reporting no study‐associated complications.<br/>There is no evidence that it was not biased. <br/>The AEs could lead to loss to follow‐up with an ophthalmologist at 1 week. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The assessment method is not detailed. However, severe adverse events are assessed by ophthalmologists using standard methods (e.g., slitlamp). <br/>The assessment of severe adverse events occurred at set time points for both groups. The chart review would have different times for each participant if all the searches were performed on a specific day rather than a follow‐up time. Phone calls and passive collection of electronic medical record data could lead to diagnostic detection bias. <br/>Any patients found to have a significant complication were immediately referred to the study ophthalmologist, who was also blinded to the patient’s group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No data analysis plan was provided. <br/>There are multiple possible definitions used and vary across the study (text message, electronic medical record, phone call, emergency department assessment, ophthalmology assessment) without a description of how these were harmonized. There is insufficient information to determine if the results were selected on this basis.<br/>There are multiple ways the data may have been analyzed. There is insufficient information to determine if the results were selected on this basis. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to missing outcome data and some concerns in selection of the reported result. </p> </td> </tr> <tr class="study-data"> <td> <p>Waldman 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer generated, block randomized sequence. "Although a different size, the medications were packaged inside the questionnaire sheets, which were concealed inside a white envelope to disguise their identity." <br/>Minimal difference between groups for reported baseline characteristics. Median baseline pain was slightly higher in the tetracaine group; 54.6 mm (10–98) versus 48.0 mm (0–96). The etiology of corneal abrasion differed between groups but could be by chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The burning sensation of tetracaine may have unblinded participants. Saline was supplied in a 5mL single‐use plastic bullet. Tetracaine was supplied in three plastic 0.5mL commercially available vials. The presence of residual rust rings is not listed as an acceptable post‐randomization exclusion in the trial registration or Methods section.<br/>The exclusions are similar between groups so it is unlikely to have influenced the direction of the effect: "Of the patients with rust rings, fluorescein uptake was seen in four of the 10 in the saline group and seven of the 13 in the tetracaine group." </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"We identified 11 patients who were noncompliant with the study protocols, four in the tetracaine group and seven in the saline group. Data analysis, however, was performed on all 116 patients enrolled into the study on an intention‐to‐treat analysis basis."<br/>There were 93. If the exclusion of participants with residual rust ring was post hoc, a number of participants had unreported outcome data. There is also unclear follow‐up beyond 48 hours. <br/>Compensating by other methods of follow‐up (call, text) reduced loss to follow‐up to 0 in both arms. The follow‐up contacts appear to have captured the missing data. The other missing data was for the retained rust rings. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The assessment methods are not detailed. The clinical tests (e.g., slit lamp, cultures) are likely to be appropriate.<br/>The tetracaine may mask complications if they are only self‐reported. Because the objective methods are not detailed, this is unclear. The subjective method may be biased towards the intervention group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registration did not exclude participants with rust rings, nor was this outlined in the Methods section. No protocol or statistical analysis plan in the registry. <br/>There were multiple time points with different participants in each. The source of collecting data may vary based on who is collecting data. The adverse events would be reported as a proportion. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to missing outcome data and bias in the measurement of the outcome, as well as some concerns due to deviations from intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Proportion of participants with complications at furthest time point</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Proportion of participants with complications at furthest time point (RD) ‐ subgroup by abrasion type</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.8.1 Post‐surgery</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Oksuz 2006</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>States the study was randomized. No information on sequence generation. No information was provided about allocation concealment. Based on the two reported baseline differences of age and sex, there is no indication of a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was reported as "single‐masked" and a researcher who evaluated the self‐reported pain scores on a VAS scale "was masked to the ointment applied," rather than the participants.<br/>There was no evidence of deviations from the intervention under the trial context. An ITT analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The authors did not report any numeric results for this outcome but simply stated that "we did not observe any corneal epithelial or ocular surface complications in either group."<br/>Not all participants were required to return after post‐op 24 hours, so there was evidence that results could be biased due to missing data.<br/>If participants dropped out for other complications but were not followed based on the epithelial healing, the missingness could depend on the true value. There are a number of participants not followed completely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>After assessing re‐epithelialization at the post‐op 24 hours (visit 1), only participants with incomplete epithelial healing were re‐examined 12 hours following visit 1 (visit 2). Patients who still had incomplete epithelization were re‐examined on post‐op day 2 (visit 3). As such, not all participants were equally likely followed for the occurrence of ocular AE. The knowledge about the treatment received either by the participants or by the caregivers who followed the participants might provide a biased follow‐up plan consciously or unconsciously.<br/>There were differences in time points based on successive assessments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no study protocol available for assessment. The authors did not report relevant definitions for ocular AE in the methods section either. There is no information about scales, assessments, or multiple time points. There is no information on how the data was analyzed. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to missing outcome data and measurement of the outcome with some concerns for bias in other domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Lim 1999</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"These subjects were randomly assigned to 7 groups of 15 eyes each according to the drug used fo the treatment of pain." However, no details were provided regarding allocation concealment or masking the participants or investigators.<br/>No information reported except for the reported mean age, age range, and sex distribution for the total study population. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"These subjects were randomly assigned to 7 groups of 15 eyes each according to the drug used of the treatment of pain." However, no details were provided regarding allocation concealment or masking the participants or investigators.<br/>No information reported except for the reported mean age, age range, and sex distribution for the total study population. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The authors did not report any numeric results for this outcome but simply stated that "No keratitis or corneal haze observed up to 1 week post‐op."<br/>There is no mention of missing data though it seems that all of the subjects were used for analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Narrative only: "No keratitis or corneal haze observed up to 1 week post‐op."<br/>Blinding of assessors is unclear. The adverse events described are more objective than subjective. Knowledge would be less likely to bias the result </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were no study protocol available for assessment. The authors did not report relevant definitions for ocular AE in the methods section either. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at some concerns of bias in four out of five domains: randomization process, deviations from intended interventions, outcome measurement, and selection of the reported result. </p> </td> </tr> <tr class="study-data"> <td> <p>Verma 1995</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Patients were allocated drops based on a random‐number generator, and prenumbered containers were dispensed by the operating surgeon." Baseline characteristics of study participants were partially reported by refractive error groups, not by treatment group. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Medications were contained in prenumbered containers and delivered by the operating surgeon who appeared to be masked too. ITT analysis of all participants. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The number of participants who lost to follow‐up was not reported by time point. It was unclear how many participants returned after post‐op week one. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The current outcome was self‐reported but was further verified by an objective surface exam (topography) and visual acuity examination for all participants who returned at week one follow‐up.<br/>The randomization code was not broken before post‐op month three. Outcome assessors were likely masked. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were reported at week one, month one, and month six as pre‐defined, except for post‐op month three.<br/>There are multiple assessments, but the reporting appears to include the details of each case. <br/>The result is dichotomous and the details of the specific assessment results are reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at a low risk of bias in all domains.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.8.2 Post‐trauma</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ting 2009</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of randomization was not described beyond stating it is a randomized trial. The research pharmacists not involved in the design or conduct of the trial, prepared identical, clear minim packs that were "sent to the ED in no particular order." <br/>There are minimal differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The containers were in clear, identical containers. The investigators did not indicate that toxicity (such as burning) prevented this. The study used a modified ITT analysis, excluding participants who had missing data at the 2 weeks assessment. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for 83% of participants randomized: 17/22 in the amethocaine group and 21/25 in the saline group (post‐hoc p &gt; 0.05). <br/>There is no evidence provided (such as a sensitivity analysis) to determine if there was biased data. <br/>The missing data could depend on its true value. During the week 2 phone interview follow‐up, the reasons reported by participants for not attending the 36‐48 hr visit was pain relief and no visual problems. There is insufficient information to determine whether this was likely to be the case or if the missing data was due to complications. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The slitlamp assessment by an emergency department physician at 36 to 48 hours is appropriate. The phone interview assessment of complications at 2 weeks is not detailed in the article, though it may not be appropriate for determining many types of adverse events. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registration does not specify assessment of complications. No trial protocol or statistical analysis plan was included. There is no information provided about how complications were assessed at the 36‐48 hr, 2 weeks, or throughout the study. <br/>There is insufficient detail to determine whether the result may have been selected on the basis of analysis. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to missing outcome data; some concerns in the measurement of the outcome and in selection of the reported result. </p> </td> </tr> <tr class="study-data"> <td> <p>Ball 2010</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Randomization key was generated via a computer using the random number function." "Staff at the hospital pharmacy diluted the proparacaine and filled numbered vials with either proparacaine or placebo. These vials were distinguishable only by number." Age and sex are the only reported baseline characteristics. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Patients were randomly assigned to groups receiving either 0.05% proparacaine or a colour‐ and smell‐ matched placebo."<br/>Staff at the hospital pharmacy diluted the proparacaine and filled numbered vials with either proparacaine or placebo. These vials were distinguishable only by number." There were 8 participants who either did not receive medications, record pain logs, or were lost to follow‐up and removed from ITT analysis.<br/>The breakdown of exclusions by reason and treatment arm is not reported. It is possible that it could have an impact on the effect estimate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A total of 8/41 (20%) participants did not contribute adverse events data to the reported effect estimate. <br/>There was no description of the reasons for missing adverse event data. <br/>It is unlikely that participants would be lost to follow‐up because of serious adverse events and that be omitted from publication. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The assessments are standard and not inappropriate. <br/>Assessments were at the same timepoints. <br/>Any patients found to have a significant complication were immediately referred to the study ophthalmologist, who was also blinded to the patient’s group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registration matches the reported outcome in the article. The outcome priorities are listed and reported. The reporting is narrative summary but is unlikely to be something other than a proportion. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to deviations from intended interventions and some concerns due to missing outcome data. </p> </td> </tr> <tr class="study-data"> <td> <p>Shipman 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation list was generated by a computer random‐number generator and randomization was performed with numbered, sealed, opaque envelopes issued in sequential order to the physician enrolling the patient in the study. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The placebo and tetracaine were labeled for the patient as the “study drops” to maintain masking. However, although we attempted to blind patients from their allocation group, the burning nature of the tetracaine may have unblinded the patients.<br/>Placebo having been packaged in 4 ampules versus the tetracaine in a single bottle. Data for all randomized participants were analyzed according to group assignment in an intention‐to‐treat fashion. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Loss to follow‐up for 3/59 (5.1%) in the tetracaine groups and 4/59 (6.8%) in the placebo group. In the tetracaine group, of the 48 patients who did not complete all follow‐ups, 16 responded to a text message, reporting no study‐associated complications. In the placebo group, 4 patients did not attend the emergency department follow‐up visit and 45 did not return for their 1‐week follow‐up with the study ophthalmologist. Of these 49 patients who did not complete all follow‐ups, 6 responded to a text message, reporting no study‐associated complications.<br/>There is no evidence that it was not biased. <br/>The AEs could lead to loss to follow‐up with an ophthalmologist at 1 week. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The assessment method is not detailed. However, severe adverse events are assessed by ophthalmologists using standard methods (e.g., slitlamp). <br/>The assessment of severe adverse events occurred at set time points for both groups. The chart review would have different times for each participant if all the searches were performed on a specific day rather than a follow‐up time. Phone calls and passive collection of electronic medical record data could lead to diagnostic detection bias. <br/>Any patients found to have a significant complication were immediately referred to the study ophthalmologist, who was also blinded to the patient’s group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No data analysis plan was provided. <br/>There are multiple possible definitions used and vary across the study (text message, electronic medical record, phone call, emergency department assessment, ophthalmology assessment) without a description of how these were harmonized. There is insufficient information to determine if the results were selected on this basis.<br/>There are multiple ways the data may have been analyzed. There is insufficient information to determine if the results were selected on this basis. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to missing outcome data and some concerns in selection of the reported result. </p> </td> </tr> <tr class="study-data"> <td> <p>Waldman 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer generated, block randomized sequence. "Although a different size, the medications were packaged inside the questionnaire sheets, which were concealed inside a white envelope to disguise their identity." <br/>Minimal difference between groups for reported baseline characteristics. Median baseline pain was slightly higher in the tetracaine group; 54.6 mm (10–98) versus 48.0 mm (0–96). The etiology of corneal abrasion differed between groups but could be by chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The burning sensation of tetracaine may have unblinded participants. Saline was supplied in a 5mL single‐use plastic bullet. Tetracaine was supplied in three plastic 0.5mL commercially available vials. The presence of residual rust rings is not listed as an acceptable post‐randomization exclusion in the trial registration or Methods section.<br/>The exclusions are similar between groups, so it is unlikely to have influenced the direction of the effect: "Of the patients with rust rings, fluorescein uptake was seen in four of the 10 in the saline group and seven of the 13 in the tetracaine group." </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"We identified 11 patients who were noncompliant with the study protocols, four in the tetracaine group and seven in the saline group. Data analysis, however, was performed on all 116 patients enrolled into the study on an intention‐to‐treat analysis basis."<br/>There were 93. If the exclusion of participants with residual rust ring was post hoc, a number of participants had unreported outcome data. There is also unclear follow‐up beyond 48 hours. <br/>Compensating by other methods of follow‐up (call, text) reduced loss to follow up to 0 in both arms. The follow‐up contacts appear to have captured the missing data. The other missing data was for the retained rust rings. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The assessment methods are not detailed. The clinical tests (e.g., slit lamp, cultures) are likely to be appropriate.<br/>The tetracaine may mask complications if they are only self‐reported. Because the objective methods are not detailed, this is unclear. The subjective method may be biased towards the intervention group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registration did not exclude participants with rust rings, nor was this outlined in the Methods section. No protocol or statistical analysis plan in the registry. <br/>There were multiple time points with different participants in each. The source of collecting data may vary based on who is collecting data. The adverse events would be reported as a proportion. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at high risk of bias due to missing outcome data and bias in the measurement of the outcome, as well as some concerns due to deviations from intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Proportion of participants with complications at furthest time point (RD) ‐ subgroup by abrasion type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Proportion of participants with complications at furthest time point (RD)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lim 1999</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"These subjects were randomly assigned to 7 groups of 15 eyes each according to the drug used fo the treatment of pain." However, no details were provided regarding allocation concealment or masking the participants or investigators.<br/>No information reported except for the reported mean age, age range, and sex distribution for the total study population. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"These subjects were randomly assigned to 7 groups of 15 eyes each according to the drug used of the treatment of pain." However, no details were provided regarding allocation concealment or masking the participants or investigators.<br/>No information reported except for the reported mean age, age range, and sex distribution for the total study population. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The authors did not report any numeric results for this outcome but simply stated that "No keratitis or corneal haze observed up to 1 week post‐op."<br/>There is no mention of missing data though it seems that all of the subjects were used for analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Narrative only: "No keratitis or corneal haze observed up to 1 week post‐op."<br/>Blinding of assessors is unclear. The adverse events described are more objective than subjective. Knowledge would be less likely to bias the result </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were no study protocol available for assessment. The authors did not report relevant definitions for ocular AE in the methods section either. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was assessed to be at some concerns of bias in four out of five domains: randomization process, deviations from intended interventions, outcome measurement, and selection of the reported result. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Proportion of participants with complications at furthest time point (RD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015091.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015091.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD015091-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015091-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015091-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015091-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD015091-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015091-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015091-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015091-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015091\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015091\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015091\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015091\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015091.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015091.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015091.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015091.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015091.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728551021"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015091.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728551024"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015091.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec73d2b55f431',t:'MTc0MDcyODU1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 